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ABSTRACT 
 In attempts to better understand the basic physiology and pathogenicity of the bovine-
pathogenic Mycoplasma bovis strain M23, we have developed genetic tools useful for M. 
bovis. Using the tools, a large scale transposon insertion mutant library was generated. 
Genetic analysis of the mutant library revealed that 324 out of 663 genes annotated in M. 
bovis were disrupted by 1,142 transposition events. By comparative genomic analysis, we 
defined 21 non-essential genes in M. bovis from among genes categorized as essential in 
other mycoplasma species, thereby, further reducing the size of the minimal genome 
complement of an independently living organism. From the mutant library, mutants defective 
in the ability to uptake thymidine were isolated. These were mutants with disruptions in the 
genes encoding the components of an ABC transport system. Substrate uptake studies proved 
that all components of the transporter are absolutely required for biological function of this 
thymidine high-affinity ABC transporter. 3H-thymidine uptake was sensitive to the presence 
of several nucleosides but insensitive to both nucleobases and pentoses, indicating that the 
transporter possesses a substrate binding protein with specificity to a portion of the broad 
chemical configuration of nucleosides, but not nucleobases or the ribose moiety. To define 
pathogenicity factors of M. bovis, a signature-tagged mutagenesis assay was developed using 
the mutant library and applied to determine the genes required for establishment of systemic 
infection and colonization on the respiratory tract of cattle. The genes identified as defective 
in non-invasive mutants were a putrescine/spermidine transporter permease gene (potC), 
uncharacterized ABC transport system permease genes, and an oligopeptide ABC transport 
system ATP-binding domain gene (oppF). Mutants of the last two genes were also unable to 
persist on the tracheal mucosa of cattle.  
 In summary, significant advances have been made in the characterization of the 
genome of M. bovis, and in the genetic manipulation of the genome. A high affinity 
thymidine transporter was characterized genetically and functionally, and several genes 
involved in pathogenicity were identified. These novel accomplishments have significantly 
advanced molecular knowledge about the biology and pathogenicity of this important 
pathogen of cattle.  
 1 
 
CHAPTER 1.  GENERAL INTRODUCTION 
 
Introduction 
Mycoplasmas belong to the class Mollicutes and are distinguished from other 
prokaryotes by the lack of a cell wall and relatively small size of their genomes. Although 
mycoplasmas parasitize a broad range of species, including mammals, birds, reptiles, fish, 
arthropods, and plants, each mycoplasma species does generally infect the restricted host 
species, with high host-specificity. Some species remain commensal but most species cause 
diseases in the infected host. Mycoplasma bovis is a highly adapted bovine pathogen causing 
a variety of diseases, such as pneumonia, mastitis, arthritis, genital and ocular disorders, and 
other conditions in dairy and beef cattle. Due to the substantial economic losses caused by M. 
bovis to the cattle industry, many efforts have been made to control this pathogen. Despite 
such efforts, little progress has been made to develop preventive means against M. bovis 
diseases. This is in part because genetic tools useful for study of this pathogen have not been 
developed to date. Without such genetic tools, it is difficult to study this pathogen’s basic 
biology as well as pathogenicity at the genetic level. For example, no definite virulence 
determinant has been identified in this pathogen to date. As with other mycoplasmas, M. 
bovis diseases are generally chronic with persistence of the infection, even if serious 
pathological consequences are not produced, indicating that its survival in the infected host, 
presumably by escape from host immune responses, may be a virulence factor. In addition, 
the mycoplasma must acquire many biological macromolecules from the host or environment 
because it lacks de novo synthetic capabilities for those as a consequence of its small genome 
capacities. Under these circumstances, we hypothesize that the survival ability of M. bovis in 
the infected host is linked to its capabilities to obtain macromolecules from the infected host. 
Consequently, M. bovis mutants that are unable to uptake such macromolecules may not be 
able to persist in the infected host. To address this concept, we developed a transposon-based 
plasmid, useful for M. bovis mutagenesis. We then perfected “high-throughput” screening 
methods and used them for the construction of a random insertion library. Mutants from this 
library were used for both determination of a transport system responsible for the uptake of 
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thymidine as a nucleoside, and for signature-tagged mutagenesis to study in vivo persistence 
and tissue invasion.  
 
Accomplishments in this study 
In this work, we developed a plasmid that can efficiently transform M. bovis, and 
used it to develop the first saturation library of random transposon mutants for this 
mycoplasma. Mutants from the library were then used to characterize an ABC transport 
system responsible for transporting nucleotide precursors from the environment. Ours is the 
first finding that Mollicutes possess an active ABC transport system involved in nucleotide 
utilization. This is a significant step in understanding how mycoplasmas can utilize essential 
nucleotide precursors and incorporate them into their nucleic acid, and the finding has broad 
application for Mollicutes other than M. bovis. In addition, we identified several non-
essential genes in M. bovis, which had previously been classified as essential genes in other 
Mollicutes, thus narrowing the definition of a “minimal genome”. This advance will also help 
to better understand the biological role of these genes. Finally, we identified three putative 
virulence genes in the pathogenic M. bovis strain M23. The genes may be involved in 
establishing systemic infection and persistence in the host, and may play an important role in 
disease production. Since these virulence genes were non-essential, they provide 
opportunities to develop better preventive strategies against M. bovis by developing mutants 
with specific gene deletions that could be used in a modified live vaccine against M. bovis 
diseases. 
 
Dissertation Organization 
This dissertation contains a general introduction, a literature review, three 
manuscripts in its main body, followed by a general summary and conclusions. Each 
manuscript contains an abstract, introduction, materials and methods, results, discussion, and 
references. The tables and figures are numbered within each manuscript. The first manuscript 
describes the establishment of a genetic tool, a transforming plasmid, and the development of 
a random insertion mutant library of M. bovis strain M23, together with a preliminary 
annotation of the genome. The second manuscript characterizes an ABC transport system 
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involved in transporting thymidine as a nucleoside. The third manuscript describes a 
signature-tagged mutagenesis assay to detect in vivo persistence and tissue invasion in cattle. 
Putative virulence factors in M. bovis strain M23 are identified.   
 
Literature Review  
Mollicutes 
 The genus Mycoplasma belongs to the family Mycoplasmataceae, the order 
Mycoplasmatales, the class Mollicutes, and phylum Firmicutes (130, 136). The class 
Mollicutes is a diverse group of cell wall-less organisms that have arisen by degenerative 
evolution from the Gram-positive bacteria branch (47, 182). The members of the Mollicutes 
are widely distributed in nature as parasites of many hosts, including mammals, birds, 
reptiles, fish, insects, arthropods, and plants (134). They possess high specificities to their 
hosts or colonizing tissues, in part, as a result of their nutrient needs and parasitic ways of 
living (22, 47, 130). There are 204 described Mollicutes species, 119 of which belong to the 
genus Mycoplasma which includes pathogens of medial importance to humans and veterinary 
species (136). Mycoplasmas are characterized as the smallest and simplest prokaryotes 
capable of self-replication and of leading an autonomous life (134). They are distinguishable 
from other bacteria by the lack of cell wall (47). The name “mycoplasma” was derived from 
the Greek word mykes meaning fungus and plasma from something molded to describe the 
fungus-like morphology (130). The terminology “mycoplasma” has been used to loosely 
describe all bacteria belonging to the class Mollicutes (47). 
 Genome of mycoplasmas 
 The genomes of Mollicutes are characterized by relatively small size in the range 
from 580 Kb (Mycoplasma genitalium G-37) (53) to 1.34 Mb (Mycoplasma penetrans strain 
HF-2) (151) and low G+C ratio (23-41 mol %) (47, 69, 183), compared to other bacteria. In 
general, the size of bacterial genome represents the number of coding genes within the 
chromosome. Accordingly, the estimated capacity of the M. genitalium genome would be 
expected to code for about 400 - 500 proteins and encodes 477 proteins by genome 
annotation (53). It was thought to contain the minimal set of genes required for independent 
life (60). Genomic analysis in mycoplasmas revealed that there are relatively greater 
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percentages of genes encoding vital functions, including DNA replication, transcription, 
translation rather than those of genes encoding metabolic pathways (47, 134). To date, there 
are 20 completely sequenced genomes from 18 species of Mollicutes, while 21 genome 
sequencing efforts are being completed (NCBI Microbial Genomes), which offers 
opportunities for genome-wide studies. Mollicutes contain 1 - 2 copies of rRNA and a limited 
number of tRNA genes (2, 131, 136). Most notable is the use of the UGA universal “stop 
codon” as a tryptophan codon in many Mollicutes (47, 62, 78, 184). However, the overall 
genome organization and mechanisms of transcription and translation in Mollicutes are very 
similar to other eubacteria (91, 133). Interestingly, due to their small genome size, Mollicutes 
have limited biosynthetic capabilities to produce molecules essential for biological functions, 
such as amino acids, vitamins, fatty acids, coenzymes, and nucleotides (14, 69, 71, 131) and 
consequently must acquire the molecules from the host or environment (130).   
 Growth requirements of mycoplasmas 
 Mollicutes are facultative anaerobes that are among the most fastidious bacteria to 
culture in artificial media (3, 109, 131). They require cholesterol, fatty acids, amino acids, 
vitamins, coenzymes, nucleic acid precursors and ions for growth (109, 133). This 
requirement can be met by adding animal sera and yeast extract to highly enriched medium 
(109, 133). Because of requirements for complicated nutrients, it has been difficult to 
establish a minimal medium for Mollicutes that would be crucial to study biochemical and 
physiological features of these organisms (109). There are a few chemically defined or semi-
defined media for Mollicutes, including those for Mycoplasma gallisepticum (167), 
Mycoplasma hyorhinis (56), Spiroplasma mirum (63), Spiroplasma floricola and 
Spiroplasma citri (93), Spiroplasma sp (23, 93), and Acholeplasma laidlawii B (169). Sterols 
and fatty acids are essential for growth of Mollicutes, except for a few species of 
Acholeplasma and Asteroleplasma (36, 145). They also need many amino acids for survival 
which can be supplied from exogenous sources (109). Vitamins and coenzymes, such as 
coenzyme A, riboflavin, nicotinic acid, thiamine, pyridoxine, biotin, folinic acid, are required 
for growth (143). In the preparation of defined media, some ions, such as K+, Mg2+, PO43-, 
have been added to maintain osmolarity of the organism. Because of lack of de novo 
synthetic capabilities for purine and pyrimidine bases (112, 131, 133), Mollicutes must 
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acquire nucleic acid precursors from the environment (14, 59, 112). Precursors for nucleic 
acids include DNA, RNA, oligonucleotides, nucleotides, nucleosides, and nucleobases (49). 
It has been reported that Mollicutes easily uptake nucleic acid precursors present in the 
medium and incorporate them into their genome (113-115). Because Mollicutes do not 
possess a functional tricarboxylic acid (TCA) pathway, they can obtain energy by glycolysis, 
oxidation of substrates, or the arginine dihydrolase pathways (47, 109). Substrates for energy 
can be glucose, glycerol, sucrose, other sugars, organic acids, or arginine (48). In Mollicutes, 
the absence of anabolic pathways for macromolecules essential for growth implies that the 
organism apparently must scavenge the macromolecules from the host or environment. 
Interestingly, proteases and nucleases produced by Mollicutes may play roles in utilizing the 
exogenous macromolecules by cleaving large units (such as proteins, polypeptides, DNA, 
RNA, oligonucleotides) to small units (a single amino acid, nucleoside, nucleobase) that then 
become available for transport (49, 127, 136, 171).   
 Pathogenesis of mycoplasmal diseases 
The diseases caused by mycoplasma infection occur as a result of interaction of 
multiple factors, including putative virulence determinants of the organism, host immune 
responses to infection, environmental factors, and the presence of other pathogens (171). 
This complex etiology makes it difficult to define a precise role of the pathogen in 
mycoplasma diseases. Mycoplasmas are frequently implicated in a wide range of clinical 
presentations in many hosts (7, 130). However, mycoplasma diseases are usually presented 
as chronic infections, indicating that the pathogens may be well adapted to conditions 
provided by the host or may not induce severe clinical manifestations due to the absence of 
strong virulence factors (171).   
 Adherence.  Attachment of microorganisms to the host cells is a crucial step to 
colonization and establishment of disease in the infected host (129, 155). In the respiratory 
tract, the organism adheres to epithelial cells and is able to resist being eliminated by the 
ciliary action and movement of the mucus blanket (31). Certain species of Mollicutes possess 
special organelles, named tips that allow them to attach to host cells (129). The tips have 
special membrane cytoadhesin proteins, such as P1, P30, P116, and HMW 1-3 in 
Mycoplasma pneumonia (155), MgPa in M. genitalium (74), P30 in Mycoplasma 
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gallisepticum (51). In other Mollicutes, adhesins are distributed around the membrane, such 
as P40 in Mycoplasma agalactiae (50), P26 protein of M. bovis (148). Attachment may 
facilitate for the organism the uptake of nutrient sources from the cells, while producing 
harmful effects on the contacted cells (129). Mycoplasmas may be able to reside on body 
sites for a long period of time, which may result in chronic infections. Thus, cytadhesins have 
long been considered a potential virulence determinant and have been extensively 
investigated. However, the ability to adhere to host cells, by itself, is not a definite virulence 
factor in Mollicutes. 
By-products.  Several by-products released from mycoplasmas have been thought to 
be putative virulence determinants. Among them, hydrogen peroxide produced by 
mycoplasma is the most well characterized factor which is relevant to pathogenesis of 
mycoplasma diseases (66, 175). Hydrogen peroxide can be produced as an intermediate 
product during metabolic processes that yield energy via oxidative pathways of substrates 
(30, 171). Hydrogen peroxide production was reported in several Mollicutes, including 
Mycoplasma mycoides subsp. mycoides, Mycoplasma pulmonis, Mycoplasma arthritidis, 
Mycoplasma neurolyticum, M. gallisepticum, Mycoplasma bovirhinitis, M. bovis, and 
Mycoplasma felis. Ciliostasis observed in mycoplasma infection was as a consequence of 
hydrogen peroxide produced in Mollicutes (30). Loss of ciliary action of epithelial cells in 
the respiratory tract can allow the mycoplasma to colonize on the cells and facilitate the 
infection of other pathogens. At the mycoplasma lesion site, the consequence has been shown 
to be tissue disruption and disorganization (20). This cell damage may also be by-stander cell 
damage derived from the host response to bacterial infection (171). However, each 
mycoplasma can differ in the degree of severity of cell damage, and type of tissue disruption, 
indicating that there are some other factors involved in this. The capability of hydrogen 
peroxide production is not always linked with pathological change, since some non-
pathogenic mycoplasmas can secrete hydrogen peroxide (122). Also, loss of virulence of 
Mycoplasma pneumoniae was not accompanied by a decrease in hydrogen production (134). 
This indicated that some other factors must be associated with the cytotoxicity of hydrogen 
peroxide. The possible factors would be the ability of the organism to keep close proximity to 
deliver a toxic effect to the cells, and a steady state concentration of toxic product to cause 
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detectable cell damage (24, 29, 32). A well characterized example is the need with M. 
mycoides subsp. mycoides SC to both produce hydrogen peroxide and attach to cells to result 
in cytotoxicity (123).   
Proteins.  Mycoplasmas have a single membrane, on which many functional proteins 
are present. Among the functional proteins, nucleases are likely to be a virulence determinant 
in Mollicutes.  Nuclease activities were found in Mycoplasma hyopneumoniae, Mycoplasma 
hyorhinis, and Mycoplasma penetrans (110). Unlike oxidative cell damage, cells exposed to 
nucleases underwent apoptosis with typical internucleosomal DNA fragmentation (110, 120, 
129, 159). Cell apoptosis can be induced by the action of either membrane-bound or purified 
mycoplasmal nucleases on cells of various origins and types (110, 120). This suggested that 
nucleases may act as a potential pathogenic determinant (120). Immunoglobulin A (IgA) 
protease can cleave IgA, which plays a predominant role in mucosal immunity to the 
organism (82). IgA protease found in Ureaplasma urealyticum cleaved IgA with selective 
host specificity, suggesting that the organism can resist the host’s immune responses (82). 
Arginine deiminase is found in arginine-utilizing species (160), including Mycoplasma 
arginine, Mycoplasma hominis, M. arthritidis, and Mycoplasma salivarium. It has been 
shown to inhibit cell proliferation by arresting the cell cycle and leads to cell death at high 
concentration (61).   
Toxins.  A few toxins have been identified in Mollicutes. A neurotoxin identified in 
M. neurolyticum (162) was the only exotoxin reported in Mollicutes. Its toxicity was shown 
when the toxin was injected intravenously but not by other injection routes, implying the 
existence of specific receptors for the toxin in the central nervous system (162). A neurotoxic 
activity was found in the extracted membrane of M. gallisepticum (166). Other toxins found 
in Mollicutes are most likely toxic membrane proteins. An inflammatory toxin was extracted 
from M. bovis and its toxicity was demonstrated by experimental inoculation into the bovine 
udder (57). Recently, a toxin having ADP ribosylating activity was identified in M. 
pneumoniae (81). The toxin structure was in part similar to that of pertussis toxin, which is 
an exotoxin derived from Bordetella pertussis (83). Uncharacterized components derived 
from membranes of Mollicutes also demonstrated toxicities in animal challenge and cell 
culture systems. The membrane extracts behaved like bacterial endotoxins whose toxicities 
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stem from the lipid A component of lipopolysaccharide of bacterial membrane (22). 
Mycoplasmas have abundant lipoproteins on their membrane, but no lipid A structures (22). 
The toxicities derived from mycoplasma membrane extracts are presumed to reside on the 
lipid moiety of lipoproteins.  
Antigenic variation.  Alteration of antigen features on the surface membrane has 
been considered a putative virulence factor in Mollicutes. Occurrence of antigenic variation 
has been reported in several Mollicutes, including M. hyorhinis (27, 185), M. bovis (8, 92), 
M. pulmonis (161), M. hominis (187), M. arthritidis (40), M. gallisepticum (95), and 
Mycoplasma synoviae (118). The antigenic variation was as a result of random DNA 
rearrangement of genes encoding the surface variable proteins of mycoplasmas (146). The 
ability to alter antigenic properties may allow mycoplasmas to escape immune recognition 
and to survive in an immune competent host (22, 92, 185). Antibody-induced pressure on a 
mycoplasma population might allow only a specific clone, which is not recognized by the 
antibody pool, to replicate and become a new population of mycoplasma, whereas the 
majority of the population recognized by the antibody pool would eliminated (92).   
 
Mycoplasma bovis 
 Mycoplasma bovis is an etiological agent causing a variety of diseases in both dairy 
and beef cattle, which include mastitis, pneumonia, arthritis, genital disorders, skin 
abscesses, conjunctivitis, otitis media, and meningitis (11, 21, 116, 121). Although M. bovis 
causes high morbidity and relatively low mortality, this pathogen is responsible for 
substantial economic loss to the cattle industry (116, 121). Costs arise because of the 
necessity of culling cows with mastitis to prevent dissemination among the herd, poor weight 
gain, treatment expenses, mortality (21, 121). M. bovis was first isolated from a case of 
severe bovine mastitis in 1961 in the USA (65), and then given its present name in 1976 (4). 
Since the initial discovery, this pathogen has been isolated worldwide and its distribution and 
incidence of infection in herds is on the rise (21, 116). This organism is now well established 
as one of the most pathogenic bovine mycoplasma species among over twenty mycoplasma 
that are capable of colonizing the bovine (121). As with a narrow host-specificity found in 
other mycoplasma species, diseases caused by M. bovis are restricted to bovine species 
primarily from domesticated bovines, bison and buffalo (116, 121). The genome size of M. 
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bovis is 1,080 Kb with a low G+C ratio of 27 to 32.9 mol% (68). M. bovis requires highly 
enriched media for growth, such as Friis broth supplemented with 20% bovine fetal serum 
because the small genome size of this organism limits its biosynthetic capability. 
Metabolically, M. bovis is one of a few mycoplasma species which use neither arginine nor 
glucose as energy sources and utilize other organic acids, such as lactate, pyruvate (84). The 
major reservoirs of M. bovis are clinically healthy cattle that do not present clinical signs but 
harbor the organism (116, 121). The organism can reside in the respiratory tract, genital tract, 
semen, and milk and can be continually shed for a long period of time (116, 121). In 
addition, M. bovis can colonize other ruminant species without presenting clinical 
manifestations (116). The major route of transmission of this pathogen into M. bovis-free 
herds is by introduction of clinically healthy cattle that are actively shedding (21, 65, 121). 
The organism can then spread rapidly in the herd by direct contact between animals or by 
fomites (116).  
 Pathogenesis of M. bovis diseases 
M. bovis is a proven pathogen associated with pneumonia, mastitis, arthritis, and 
genital infections in cattle (21, 121). Despite clear evidence of its pathogenic potential, little 
is known about its mechanisms of pathogenesis (102, 116). Rather, it has been suggested that 
M. bovis diseases result from combination of multiple factors which are derived from the 
mycoplasma, host and/or environment (116, 121).  
The attachment of mycoplasmas to host cells is an essential prerequisite for 
colonization of host cells and initiation of infection (31, 129, 142).  The potential of M. bovis 
to adhere to bovine cells, such as alveolar macrophages (73) and neutrophils (164) has been 
demonstrated, indicating that M. bovis may possess some components related to attachment. 
The P26 protein of M. bovis has been reported to be involved with adherence processes 
(150). Its binding receptor may be sialic acid moieties of host cells since the adherence rate 
of M. bovis was significantly reduced by treating host cells with neuraminidase (148). As 
another component involved in attachment, variable surface proteins allow the organism to 
interact with host cells (149), allowing a wide range of avidity and specificity of binding. 
However, no difference in adherence capacity of M. bovis between pathogenic and non-
 10 
 
pathogenic strains has been reported (163), indicating that adherence can not serve as a 
stand-alone pathogenicity factor.   
Variable surface proteins (VSP) of M. bovis have been known to contribute to 
phenotype variability of this organism and to be involved in the process of cytadhesion to 
host cells (149). The expression of VSPs is characterized by high frequency of phase and size 
variation caused by non-coordinated DNA rearrangements in the region coding vsp genes (8, 
92, 101, 185). Variability of antigenic features may affect the characteristic of the 
mycoplasma surface, resulting in avoidance of host immune recognition, and facilitating 
adaptation to different conditions in the host and environment (22, 92, 149). In addition, 
antibody-induced clonal selection on mycoplasma cells has been demonstrated in M. bovis, 
suggesting that any variant clone among the organism population which are resistant to 
antibody-mediated inhibition may be selected under the host’s immune pressure, and result in 
a new surviving population (92). Thus, the ability of M. bovis to alter antigenic features can 
be regarded as part of the strategies of the pathogen for subverting host defense systems (92, 
119). It has been reported that M. bovis was able to adhere to neutrophils and macrophages 
and inhibit their phagocytic activity for a short period of time but was destroyed by 
phagocytes in the presence of antibody (72, 73). This indicated that the organism is capable 
of avoiding early phagocyte effects and cell-mediated immune response, helping it to survive 
from attack by the host immune system (164). The putative factor related to this phenomenon 
has not been identified yet. The occurrence of suppressive immune responses in the host 
infected with M. bovis has been reported (9, 10), and was characterized by both delayed- 
humoral immune responses and suppression of cellular-mediated immune responses (9, 10, 
165). In addition, mitogen-induced lymphocyte blastogenesis was suppressed by adding M. 
bovis cells or culture supernatant (15, 16, 165). Recently, it was reported that a factor 
responsible for suppression of lymphocyte blastogenesis is the external C-terminal of a 
variable surface protein of M. bovis (173). This factor can be assumed to be potentially 
relevant to alteration of immune responses of the host.   
The production of hydrogen peroxide is widely believed to play an important role in 
mycoplasma pathogenicity (136), causing peroxidation of lipid membranes of eukaryotic 
cells, cell cycle arrest, and inhibition of ciliary action of the trachea (171). In M. bovis, 
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hydrogen peroxide can be produced during the oxidation of organic acids (108). The 
production of hydrogen peroxide in M. bovis was variable among strains, and reduced after in 
vitro passages (85). In vitro passage of more than 60 times markedly reduced the virulence 
for the mammary gland of experimentally infected mice, compared to the original strain 
(168). Thus, it has been assumed that the production of hydrogen peroxide may be related to 
pathogenicity, but the correlation between hydrogen peroxide production and pathogenicity 
of M. bovis has not been confirmed in animal models.  
A polysaccharide toxin of M. bovis was reported as a cell-membrane associated heat- 
stable inflammatory toxic substance (57). No further follow-up study on this toxin was 
reported. Recently, biofilm formation was reported in M. bovis, which was strain-dependent 
and associated with specific Vsp expression; VspO and VspB expression correlated with 
biofilm formation (106). Since bacterial biofilm formation has been known to be associated 
with colonization on host cells (35), the ability of M. bovis to form a biofilm may be 
considered a putative virulence determinant. 
 
Nucleotide metabolism 
 Nucleotides have essential roles in all biological aspects of living cells, such as 
synthesis of carbohydrates, lipids, proteins, coenzymes, nucleic acids, and intermediates for 
energy-related reactions (177). Most importantly, nucleotides serve as a building block for 
synthesis of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). Nucleotides consist 
of a [deoxy-] ribose, a nucleobase (either purine or pyrimidine), and phosphate(s). Adenine, 
guanine, and hypoxanthine belong to purine bases, whereas uracil, cytosine, and thymine do 
to pyrimidine bases. The nucleotides can be synthesized by either a de novo pathway or a 
salvage pathway in living cells (177). 
 Nucleotide synthesis by de novo pathway 
Purine ribonucleotides are synthesized from simple compounds, such as ribose, amino 
acids, CO2, NH3, and phosphoribosyl pyrophosphate (PRPP), as a result of series of 
enzymatic reactions (177). For purine nucleotide, inosine monophosphate (IMP), the initial 
purine nucleotide, is synthesized via de novo synthetic pathway (177). Adenosine 
monophosphate (AMP) is synthesized from IMP by the action of adenosylsuccinate 
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synthetase and adenosuccinate lyase, whereas guanosine monophosphate (GMP) is 
synthesized from IMP by the action of IMP dehydrogenase and GMP synthase (177). 
Adenosine triphosphate (ATP) is converted from AMP by adenylate kinase (ADK) and 
nucleoside diphosphokinase (NDK), whereas guanosine triphosphate (GTP) is converted 
from GMP by the action of GMP kinase and NDK. For pyrimidine nucleotides, orotidine 
monophosphate (OMP), the first pyrimidine nucleotide, is synthesized from simple 
compounds and can be converted to uridine monophosphate (UMP) by the action of orotate 
phosphoribosyltransferase (177). The UMP can be used to synthesize cytidine triphosphate 
(CTP) from UTP by the action of CTP synthetase after UTP formation from UMP by the 
action of NDK. For synthesis of deoxyribonucleotides (dNTP), dexoyribonucleoside 
triphosphates (dATP, dCTP, dGTP) can be formed directly from the corresponding 
ribonucleoside triphosphates (ATP, CTP, GTP) by replacing the 2’-OH group with hydrogen 
by the action of ribonucleotide reductase (RNR) (177). Alternatively, they can be formed 
from deoxyribonucleoside diphosphates (dADP, dCDP, dGDP) by the action of NDK or 
from ribonucleoside monophosphate (AMP, CMP,GMP) by the action of RNR and NDK 
(177). For synthesis of deoxythymidine triphosphate (dTTP), deoxyuridine monophosphate 
(dUMP) can be synthesized from UMP, by the methylation of UMP by thymidylate synthase 
with a methyl donor (N5, N10-10-methylenetetrahydrofolate) (177). Then, dUMP can be 
converted to deoxythymidine monophosphate (dTMP) by the action of thymidylate synthase, 
and to deoxythymidine triphosphate (dTTP) by the action of thymidylate kinase and NDK.  
 Salvage pathway for nucleotide synthesis  
Certain organisms cannot synthesize nucleotides because they do not have enzymes 
involved in de novo pathways for nucleotide synthesis (131, 170, 177). In that case, the 
organism must have alternative pathways to synthesize the nucleotides essential for living 
organisms. In most cells, nucleic acid materials are actively broken down to nucleobases, 
nucleosides, nucleotides, or ribose-moieties and synthesized by their salvage pathway (170, 
177). In the salvage pathway, these precursors can be converted into the corresponding new 
nucleotides by the multiple enzyme reactions involved in salvage processes (170, 177). As an 
important compound for salvaging nucleotide precursors, [deoxy-] ribose-5-phosphate can be 
generated from either glucose-6-phosphate derived from the oxidative branch of the pentose 
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phosphate pathway or be supplied from the environment (170). The pentose phosphate 
pathway is a critical component of the salvage pathway, and is involved in NADPH 
production, conversion of hexoses to pentoses, and pentose degradation (125, 170). 
Alternatively, deoxynucleotides can be supplied as pre-existing precursors from the 
environment and can be converted to the corresponding dNTP by phosphorylation (18). In 
this reaction, phosphopentomutase is a key enzyme that interconverts [deoxy]-ribose-5-
phosphates and [deoxy]-ribose-1-phosphates, thus permitting pentose to ribosylate both 
purine and pyrimidine bases to synthesize the corresponding nucleotides (18, 128, 170). In 
organisms where the phosphopentomutase gene is disrupted, rich growth medium can be a 
source of pentose (125). Nucleosides can be deribosylated to nucleobases by purine- or 
pyrimidine- nucleoside phosphorylase activities, leaving ribose-moieties that can be utilized 
for new nucleoside synthesis. Nucleobases can be converted to the corresponding nucleoside 
monophosphates by the activities of adenine phosphoribosyltransferase (APRT), 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT), and uracil 
phosphoribosyltransferase (UPRT) (14). In contrast to the purine salvage that extensively 
reutilizes purine bases, pyrimidine bases are poorly utilized and strictly regulated.  
 Nucleotide metabolic pathways in Mollicutes 
The parasitic lifestyle of Mollicutes allow them a rich supply of preformed 
macromolecules, including nucleotide precursors (47, 49). Their nutritional fastidiousness 
has resulted in difficulty in determining the nutrient substances essential for growth (124). 
Early studies reported that various nucleotide precursors, mostly nucleobases, are required 
for growth of several species of Acholeplasma (132, 158). Guanine, uracil, and thymine were 
the simplest requirements for growth in M. mycoides subsp. mycoides (62). In further study, 
guanine can be converted to all purine nucleotides when guanine is a source for purine, and 
uracil can meet the requirements for pyrimidine nucleotide synthesis M. mycoides subsp. 
mycoides(144). The ability to utilize nucleotide precursors was dependent on species of 
Mollicutes, indicating that each mycoplasma species may possess different capabilities for 
nucleotide salvage. Uridine phosphate synthesis can be from uracil and PRPP by the action 
of UPRT, followed by NMK and NDK activities, whereas cytosine phosphate can be 
synthesized from UPT by the activity of CTP synthase. Alternatively, nucleotides can be 
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converted from the corresponding nucleosides by the action of cytidine/uridine kinase. 
Adenosine phosphates can be formed from guanosine phosphate, but the guanosine 
phosphates can not be formed from IMP in M. mycoides subsp. mycoides. In this case, 
guanine will be absolutely required for growth. Synthesis of dTMP can be from dUMP by the 
action of thymidylate synthase, which occurs in many bacteria (177). The dTMP can convert 
to dTTP by the action of thymidine kinase and thymidine deoxythymidine diphosphate 
kinase (177). In certain species, thymine or thymidine were absolutely required for growth, 
indicating that thymidylate synthase which converts dUMP to dTMP is probably absent 
(179). The absence of thymidylate synthase was confirmed in the sequenced genomes of M. 
hyopneumoniae (111), and M. mycoides subsp. mycoides (179). In this case, the dTMP pool 
would be dependent on the direct uptake from environment (111, 179) or by the concerted 
action of thymidine phosphorylase and thymidine kinase activities on uptake of thymine 
derivates (14).This implies that such species must have active systems to transport thymine 
derivatives through their impermeable membrane (17, 49, 186). The potential existence of 
such transporters was experimentally demonstrated in M. mycoides. subsp. mycoides (107, 
112). Furthermore, several enzymes required for salvaging nucleotides have been identified 
in Mollicutes, such as purine phosphorylase, and phosphopentomutase. By comparative 
genomic analysis, the existence of putative transporters potentially involved in transporting 
nucleotide precursors has been deduced from several sequenced genomes of Mollicutes (17, 
53, 124).  
 
ATP-binding cassette (ABC) transport systems 
 The ATP-binding cassette (ABC) transport systems constitute one of the largest 
superfamilies of paralogous sequences (38) which are widespread among living organisms 
(38). The structure of ABC transport system generally consists of an ATP-binding domain, 
one or two transmenbrane domains (TMD), and a substrate binding domain (SBP) (37). 
ATP-binding domains contain highly conserved motifs (Walker A and B) that bind and 
hydrolyze ATP, supplying energy for either uptake or efflux of various substrates (37). The 
TMDs are to form a membrane channel to allow substrate transport. They also possess a 
highly conserved motif, called EAA loop, which binds the ATPase domain on the 
 15 
 
cytoplasmic side of the membrane. SBPs interact with their cognate TMDs, trigger ATP 
hydrolysis in the ABC transport system and initiate substrate transport, once binding with 
proper substrates occurs (37). In Gram-negatives, SBPs are located in the periplasmic space 
as soluble free forms, whereas in Gram-positive bacteria, they are anchored on the membrane 
via lipid tails as lipoproteins. The flexible and external SBPs are located in close proximity to 
the protruding cognate TMDs (37, 117). The capture of substrates via SBPs is commonly via 
hydrogen bonding between SBP binding pocket and specific configurations of substrates. 
This bond exhibits extremely high affinity to the substrate, showing a high Vmax and low Km. 
 Biological roles of ABC transport systems 
Unlike the outer membrane of Gram-negative bacteria, the bacterial cytoplasmic 
membrane is impermeable to almost every solute unless a special transporter system is 
provided (1). However, bacteria require specific molecules essential for survival and uptake 
them across the cytoplasmic membrane (70). This indicates that transporters capable of 
transporting the molecules through the cytoplasmic membrane must exist. The importance of 
transporters in bacterial cells is exemplified by the fact that almost 20% of the E. coli genes 
so far identified are associated with transport functions (5). ABC transporters can serve as 
uptake or export systems in living organisms (70). The uptake function of ABC systems is 
absent in eukaryotes, whereas, in prokaryotes, the primary role of ABC systems is to serve as 
uptake systems that acquire a broad range of nutrients, such as amino acids, carbohydrates, 
peptides, vitamins, etc (37, 138). As exporters, ABC systems are involved in efflux of 
substrates, including cell surface components, proteins involved in pathogenesis, drugs, etc 
(37).   
 ABC transporters in Mollicutes  
The necessity of active transport systems to uptake certain nutrients is obvious in 
Mollicutes because they lack many biosynthetic pathways essential for survival that are 
present in other bacteria (53). Consequently, mycoplasmas must rely on an external supply 
for the nutrients (134). The existence of amino acid transporters in Mycoplasma fermentans 
and M. hominis (135), and sugar transporters in M. gallisepticum (147) has been suggested, 
with these behaving like typical microbial permease systems. To obtain all required nutrients, 
a substantial portion of a Mollicutes genome must be diverted toward transport systems (17, 
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53, 134). This suggestion has been supported by annotation results of complete genomes of 
Mollicutes (14). Several ABC transport system have been described such as glycerol ABC, 
sugar ABC, oligopeptide ABC, and polyamine (spermidine/putrescine) ABC transporters. 
The potential existence of transport system was searched on the list of complete genomes of 
Mollicutes that are currently available (NCBI Microbial Genome). They include Mycoplasma 
agalactiae PG2 (CU179680), Mycoplasma arthritidis 158L3-1(CP001047), Mycoplasma 
capricolum subsp. capricolum ATCC 27343 (CP000123), Mycoplasma gallisepticum R 
(AE015450), Mycoplasma genitalium G37 (L43967), Mycoplasma hyopneumoniae 232 
(AE017332), Mycoplasma mobile 163 K (AE017308), Mycoplasma mycoides subsp. 
mycoides SC str. PG1 (BX292980), Mycoplasma penetrans HF-2 (BA000026), Mycoplasma 
pneumoniae M129 (U00089), Mycoplasma pulmonis UAB CTIP (AL445566), and 
Mycoplasma synoviae 53 (AE017245).  
Glycerol transporters are found in M. agalactiae, M. capricolum subsp. capricolum, 
M. mycoides subsp. mycoides, M. synoviae, but not M. arthritidis, M. gallisepticum. In some 
species, an alternative protein, a glycerol facilitator protein, may serve this function, such as, 
is found in M. genitalium, M. hyopneumoniae, M. mobile, M. penetrans, and M. pneumoniae. 
Polyamine transporters are found in M. agalactiae, M. arthritidis, M. capricolum subsp. 
capricolum, M. genitalium, M. hyopneumoniae, M. mobile, M. mycoides subsp. mycoides, M. 
pneumoniae, M. pulmonis, M. synoviae but not in M. gallisepticum. Polyamines (spermidine, 
spermine, and putrescine) are ubiquitous polycations in cells, and they play important roles in 
various aspects of cell biology (140, 154). Due to absence of the polyamine synthesis 
pathway, existence of a polyamine transporter should be indispensible in Mollicutes. 
Oligopeptide transporters are found in M. agalactiae, M. arthritidis, M. capricolum subsp. 
capricolum, M. genitalium, M. hyopneumoniae, M. mobile, M. mycoides subsp. mycoides, M. 
penetrans, M. pneumoniae, M. synoviae, but not M. gallisepticum. Sugar ABC transporters 
are found in all Mollicutes annotated, including M. agalactiae, M. arthritis, M capricolum 
subsp. capricolum, M gallisepticum, M. genitalium, M. hyopneumoniae, M. mobile, M. 
mycoides subsp. mycoides, M. penetrans, M. pneumoniae, M. pulmonis and M. synoviae. 
This ubiquitous existence of sugar ABC transporters in Mollicutes suggests that this 
biological role could be conserved and absolutely essential for survival of Mollicutes. To 
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date, only a few active transport systems in Mollicutes have been described and characterized 
with experimental confirmation. In M. mycoides subsp. mycoides, the glycerol ABC 
transporter, gtsABC, was identified and characterized in terms of its relevance to a role in 
pathogenesis (123, 175). The biological role of the polyamine transporter in Streptococcus 
pneumonia has been described, and its relationship to virulence of the organism was 
demonstrated (152, 178). Unfortunately, no study has been made to characterize the 
biological and pathogenic roles of ABC transporters (polyamine, oligopetide, sugar ABC) in 
Mollicutes, except for the glycerol transporter (gtsABC) of M. mycoides subsp. mycoides. 
This may be partially due to the difficulty in generating isogenic mutants in absence of the 
proper genetic tools.    
 Implication of ABC transporters in Mollicutes 
 It has been reported that ABC transporters were involved in pathogenicity of bacteria, 
including Streptococcus pneumoniae (153, 178), Agrobacterium tumefaciens (105), and M. 
mycoides subsp. mycoides (123, 175). In M. mycoides subsp. mycoides , a virulent strain 
(African-) contains the glycerol transporter (gtsABC), whereas an avirulent strain (European-
) does not (174), indicating that the ability of glycerol uptake via gtsABC is related to the 
pathogenicity of the organism. Hydrogen peroxide, a well-known virulence factor in 
Mollicutes, was produced in the virulent strain that has intact gtsABC, and the produced 
hydrogen peroxide injured the host cells closely in contact to mycoplasma cells (175). This is 
the best and only ABC transport system whose function was characterized with experimental 
data in Mollicutes to date (66, 123, 175). Polyamine (spermidine/putrescine) transporters are 
found in most species of Mollicutes annotated to date, indicating that they are involved in 
important biological functions (140, 154). In S. pneumoniae, inactivation of potC and potD 
(polyamine transporter) resulted in loss of virulence of the organism in experimentally 
challenged mice. In addition, mice vaccinated with the protein PotD (a substrate binding 
protein) were protected against systemic infection with wild type challenge (153). 
Furthermore, it has been shown that a potC mutant of M. bovis strain M23 lost its ability to 
invade deep tissues of challenged calves (Lee and Rosenbusch, unpublished data). The potC 
is an integral transmembrane component of polyamine ABC transporter of M. bovis, 
indicating that a mycoplasma polyamine transporter is involved in virulence of this organism. 
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Importantly, transporter component proteins involved in transport of essential substrates for 
survival should be biologically conserved. For example, a substrate binding protein can be a 
structurally stable and conserved protein among strains of a target Mollicutes species. Such 
proteins can be good candidates for vaccine or diagnostic tool development for Mollicutes 
(117).   
 
Gene inactivation in Mollicutes 
 Bacterial genes can be inactivated by various ways, such as conjugation, transfection, 
transduction, and transformation (41, 42). Using these systems, new isogenic mutants can be 
generated from the wild type of the organism, which provides opportunities to investigate 
gene functions by comparison of the mutant with wild type. Establishment of reliable genetic 
tools is thus a crucial step to study the basic biology of an organism. 
 Gene transfer in Mollicutes 
The first transfection in Mollicutes was demonstrated by simply adding mycoplasma 
virus onto lawn-grown A. laidlawii (97). Other transfection methods of Mollicutes have been 
developed, which include polyethylene glycol (PEG)-mediated transfer (156, 157), and the 
electroporation method (98). Conjugation was also reported as a means of transferring the Tn 
916 genetic element to M. hominis and other Mollicutes (6, 103, 141). The first attempt to 
transform Mollicutes was made using mycoplasmas treated with divalent cations and the 
PEG-mediated method (55, 156). Electroporation was used to deliver genetic material into S. 
citri (98). Since then, the electroporation method has been widely used to transform 
Mollicutes due to its high transformation frequency and its simple procedure.   
Autonomously replicating plasmids are a useful genetic system that is widely used in 
many bacteria. However, very few plasmids were found to naturally occur in Mollicutes. The 
first cloning vector for Mollicutes was developed using a cryptic plasmid that was isolated 
from M. mycoides subsp. mycoides. The plasmid carrying both the origin of replication of the 
chromosome (oriC) sequence from E. coli and tetM for antibiotic selection was constructed 
(12, 13, 46). Once plasmid (pIK∆) isolated from the transformed host was reintroduced into 
M. mycoides subsp. mycoides, the plasmid was stably maintained in the transformed cells, 
indicating that it would be a suitable mycoplasma vector (86, 88). An alternative method to 
construct self-replicating oriC plasmids was developed in M. pulmonis.  A plasmid carrying 
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the oriC fragment derived from M. pulmonis and the tetM gene was introduced into M. 
pulmonis and maintained stably in the transformed cells (34). This indicted that a short oriC 
region is required for construction of self-replicating plasmids in Mollicutes. With this 
strategy, oriC plasmids have been constructed in several species of Mollicutes and are being 
used for inactivation of target genes, expression of foreign proteins, or complementation tests 
(80, 94).   
 Transposons 
Transposons are genetic elements that are able to randomly integrate into the 
chromosome of a recipient organism. Transposon Tn 916 , isolated from the Gram-positive 
Enterococcus faecalis (52), is a 18 Kb transposable element that consists of the xis-Tn/int-Tn 
gene for excision/integration, the tetracycline resistance (tetM) gene, and a set of genes (tra) 
required for intercellular transfer (28). In Mollicutes, plasmid pAM 120 carrying Tn 916 was 
first introduced into A. laidlawii (44), showing that the genetic element was transposed to 
diverse sites within the recipient chromosome. Tn 916 has been used to transform several 
species of Mollicutes, including M. pulmonis (44), M. hyorhinis (43), M. mycoides subsp. 
mycoides (87, 181), M. gallisepticum (19), M. hominis (141), and M. arthritidis (176). 
Transposon Tn 4001 is a 4.8Kb transposable element which was isolated from 
Staphylococcus aureus (99). It consists of two identical inverted repeats (IS256) of 1.35 Kb 
and the aacA-aphD gene encoding a bifunctional aminoglycoside modifying enzyme that 
confers resistance to gentamicin, tobramycin, and kanamycin (89, 99, 100). Tn 4001 has been 
widely used for Acholeplasma (104), and M. gallisepticum (19), M. pneumoniae (67), M. 
genitalium (137), M. arthritidis (45), M. pulmonis (104). Like Tn 916, transposon Tn 4001 
was randomly distributed at diverse sites in the recipient chromosome. In addition, pISM 
2062 a derivative of Tn 4001 was developed with unique restriction enzyme sites (BamHI, 
SmaI) to facilitate genetic manipulation (90). This plasmid is widely used to generate random 
insertion mutants or introduce genes into the chromosome of the recipient organism. Another 
Tn 4001 derivative, named mini-Tn 4001tet, was constructed, whose transposase gene is 
located outside the transposon elements, to prevent potential re-excision of the transposon 
after the first transposition event (126).   
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 Approaches for gene inactivation in Mollicutes 
 Gene inactivation of microorganisms can be accomplished by either inactivation of a 
target gene or by a random insertion mutation. The direct disruption of target genes in 
Mollicutes was first reported in M. genitalium accomplished by double homologous 
recombination by using a suicide plasmid (39). Since this report, no other successful example 
has been reported in Mollicutes, even though the strategy is being used in many bacteria. It is 
thought that the homologous recombination event is extremely rare in Mollicutes, possibly 
due to either the absence or low activity of the enzymes involved in the homologous 
recombination event. An alternative method to disrupt target genes is to use an oriC plasmid 
that carries the homologous sequences required for cross-over between the plasmid and the 
target gene within the recipient chromosome. After introducing the oriC plasmid into the 
organism, the transformant is maintained for several passages in the presence of antibiotic 
pressure to facilitate the homologous recombination event between the cloned target gene in 
the oriC plasmid and the corresponding gene within the chromosome. Then, non-integrated 
plasmids can be removed by passing the cells in antibiotic-free medium. With this strategy, 
direct gene inactivation has been reported in S. citri (34, 139), M. capricolum subsp. 
capricolum (80), M. agalactiae (26), M. gallisepticum, and M. imitans (94).   
 It would be impossible to inactivate specific target genes in certain Mollicutes like M. 
pneumonia where enzymes participating in homologous recombination events are not 
expressed. In this case, mutant defective in the gene of interest can be accomplished by 
generating a random mutant library followed by selection of desirable clones. Selection of a 
specific mutant out of the mutant library can be carried out by various methods, including 
phenotype change, immunoblotting, PCR assay, and direct sequencing of insertion sites in 
the whole library (64). In many aspects, a random insertion mutant library covering enough 
mutants to saturate the entire non-essential gene complement of an uncharacterized organism 
would provide rich opportunities to study the basic biology and functional genomics of the 
organism, which include the physiology, biochemical pathways, virulence determinants, 
essential genes, transporters, and regulatory systems, etc. This also would be a desirable 
approach for many Mollicutes, where genetic tools for the Mollicutes have not been 
developed. To date, random mutant libraries have been constructed in M. pulmonis (54), M. 
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genitalium (53), M. pneumoniae (77), M. gallisepticum (180), M. arthritidis (79) and M. 
bovis (Lee and Rosenbusch, unpublished data). As an application of random mutant library 
studies, the number of minimal genes for a self-living organism has been determined in M. 
genitalium, the smallest mycoplasma (58, 76). Since then, the absolute number of minimal 
genes has been updated, by analysis of the disrupted genes within random mutant libraries 
constructed in other Mollicutes (54, 58, 77). To determine putative virulence determinants of 
pathogenic microorganisms, signature-tagged mutagenesis using in vivo virulence assays has 
been used in many bacteria (25, 33, 96, 172), M. gallisepticum (75), and M. bovis (Lee and 
Rosenbusch, unpublished data). With recent progress in developing genetic tools, the 
availability of the genome sequences, and the construction of random mutant libraries, it will 
be possible to better understand the Mollicutes in the near future.  
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CHAPTER 2.  GENOME CHARACTERIZATION OF MYCOPLASMA BOVIS 
STRAIN M23 BY MEANS OF A RANDOM INSERTION MUTANT LIBRARY 
 
Abstract  
 Mycoplasma bovis is the etiological agent for several diseases of cattle and causes 
substantial economic losses to the cattle industry. Despite its economic significance, limited 
progress has been made in understanding the biology and pathogenicity of this mycoplasma, 
due to the lack of efficient tools to genetically manipulate the pathogen. In this study, we 
constructed a Tn4001-based plasmid (pRIT-1) carrying tetracycline resistance. Using 
plasmid pRIT-1, a total of 1,340 random mutants of the pathogenic M. bovis strain M23 was 
generated, sequenced, and evaluated. By comparison with the annotated Mycoplasma 
agalactiae PG2 genome and the arbitrarily annotated M. bovis PG45 genome, we obtained 
1,142 distinct transposon insertion sites in the chromosome of M. bovis mutants. With further 
analysis, 324 genes out of 663 genes assigned to M. bovis were disrupted by transposon 
insertion events. Relative to genes categorized as essential in other mycoplasmas, 21 were 
identified as dispensable genes in M. bovis. The availability of a random mutant library will 
open an avenue to study the biology and pathogenesis of M. bovis.  
 
Introduction 
 The availability of a large number of complete genome sequences has significantly 
aided functional exploration of the genes of a variety of microorganisms (20, 28). In addition 
to the increasing genomic information, there have been many advances in molecular 
techniques used to define functions of bacterial genes, including bioinformatics, comparative 
genomics, and functional genomics (1, 22, 28). This combination of massive databases and 
advanced techniques has resulted in markedly improved understandings about bacterial 
biology. However, there are still challenges remaining in determining the function of many 
genes encoded by microorganisms, including those genes involved in pathogenicity of 
specific prokaryotes (22, 23, 28). One of the possible ways to address this issue is to generate 
a large number of mutants and then determine the phenotypes of the resulting organisms (1, 
4, 11). Thus, establishment of global mutagenesis approaches can be a significant step 
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towards dissecting the biological function of genes of uncharacterized microorganisms. This 
global mutagenesis strategy has been proven as a powerful method to study bacterial biology 
as well as to determine virulence factors in numerous bacterial pathogens (1).  
 In Mollicutes, the complete genome sequences of 13 strains representing 11 species 
are currently in the public domain, and at least 12 additional strains are currently being 
sequenced. Despite this wealth of mycoplasma genomic sequence data, relatively limited 
progress has been made in studying functional genomics because of a lack of tools to 
genetically manipulate these organisms. Global mutagenesis has been initially employed in 
Mycoplasma genitalium (7), the smallest self-replicating microorganism, and further 
expanded to Mycoplasma pneumoniae (13), Mycoplasma arthritidis (6), and Mycoplasma 
pulmonis (8). In a pathogenicity study, signature-tagged mutagenesis was used to identify a 
virulence-associated gene in Mycoplasma gallisepticum (12). To search for desirable 
mutants, a large scale transposon mutagenesis has been applied in Mycoplasma mycoides 
subsp. mycoides (14).  
 Mycoplasma bovis is a pathogen that causes substantial economic losses to the cattle 
industry. This pathogen is responsible for calf pneumonia, mastitis, arthritis, and other 
conditions (21, 25). The economic significance of this pathogen has led to extensive studies 
to develop diagnostic methods and preventive measures against M. bovis disease, the latter 
with limited success due to a lack of knowledge about pathogenicity markers. The limited 
availability of genetic tools for this pathogen has made it difficult to study the basic biology 
and pathogenicity of the microorganism, and thus to improve approaches for prevention and 
control of M. bovis infection. Transformation of M. bovis with a transposon-based plasmid 
was reported as feasible in a preliminary study (3). Here, we report the construction of a 
transposon-carrying plasmid that is able to confer tetracycline resistance, and the 
development of a random insertion mutant library from the pathogenic M. bovis strain M23. 
Sequencing of transposon insertion sites on the mutants allowed the preliminary assignment 
of inserts to genes defined on an unannotated genome database for M. bovis. This mutant 
library now provides opportunity to explore the biology and pathogenicity of M. bovis.  
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Materials and Methods 
Bacterial strains and culture conditions 
 The pathogenic M. bovis strain M23 has been isolated from a respiratory infection 
case in calves (27), and was grown in modified Friis medium (16) supplemented with 20% 
fetal calf serum in 2% CO2 at 37˚C. Strain M23 was used as the parent strain to generate 
transposon insertion mutants. This strain is highly sensitive to tetracycline (complete 
inhibition of growth at 2 µg/ml tetracycline). Mycoplasma transformants were selected on 
Friis agar plates (2 µg/ml tetracycline) and maintained in Friis broth (2 µg/ml tetracycline). 
For plasmid manipulation, Escherichia coli DH5α was grown in Luria-Bertani (LB) broth or 
agar. Either ampicillin (50 µg/ml) or tetracycline (5 µg/ml) was added to LB broth or plates, 
as required. 
 
Plasmid construction 
 Plasmid pISM 2062 (15), pISM 1002 (19), and mini-Tn4001tet (26) were graciously 
provided by F.C. Minion (Iowa State University). Plasmid pISM 2062 was used as a parent 
plasmid for constructs. It harbors a modified Tn4001 containing the aacA-aphD gene for 
resistance to gentamicin/tobramycin/kanamycin (2). pISM 1002 that carries tetracycline 
resistance gene derived from Tn 916 was used to clone the tetM. The 4.98 Kb HincII 
fragment containing the tetM gene from plasmid pISM 1002 was collected from an agarose 
gel resolved by electrophoresis and purified (Gel Extraction Kit, Qiagen). Plasmid pISM 
2062 was digested with SmaI, treated with calf intestinal alkaline phosphatase, and purified 
(PCR Purification Kit, Qiagen). SmaI-digested pISM 2062 was ligated to the tetM fragment 
derived from pISM 1002. The resulting plasmid (Figure 1) was named pRIT-1. The plasmid 
pRIT-1 construction was confirmed by restriction enzyme digestion and direct sequencing. 
The plasmid was amplified in E. coli DH5α and used for M. bovis transformation.  
 
Transformation and mutant recovery 
 Mycoplasma transformation was performed as described previously (3, 26). Briefly, 
one ml of mycoplasma grown to the designated growth phase in Friis broth was harvested by 
centrifugation (10,000 g, 20 min, at 4 ˚C). The cells were washed three times in 1 ml chilled 
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electroporation (EP) buffer (8 mM Hepes, 272 mM sucrose, pH 7.4) by centrifugation as 
described above. After the final wash, the cell pellet was resuspended in 100 µl of chilled EP 
buffer and placed on ice. A designated amount of plasmid DNA (pRIT-1, pISM 2062, or 
mini-tn4001tet) was added to the cells and the mixture placed on ice for 30 min. The cells 
were subjected to electroporation at 2.5 kV and 36 µF in electroporation cuvettes with 2 mm 
gap. The electroporated cells were transferred to 900 µl of antibiotic-free Friis broth and 
allowed to recover at 37°C for 2hr. An aliquot (100 µl) of the cells was then spread onto Friis 
agar plates (2 µg/ml tetracycline) at dilution sufficient to recover about 20 colonies per 150 
mm plate. The plates were placed at 37°C until colonies appeared after 4-5 days. A total of 
3,155 transformed colonies was picked using glass Pasteur pipettes, grown in 2 ml Friis broth 
(2 µg/ml tetracycline), and stored at – 70 °C for further analysis.  
 
Analysis of Tn 4001 insertion site  
 To analyze the Tn4001 insertion site in individual clones, total genomic DNA was 
extracted from 10 ml Friis broth culture (DNA Blood Mini Kit, Qiagen). Five µg of genomic 
DNA was subjected to one-directional sequencing at the Iowa State University DNA facility. 
The sequencing primer used was the Tn 4001-specific primer  
(5’-CGAGGGATTCCGAGGACTG-3’), matching sequence located on the outward end of 
the tetM fragment inserted into pRIT-1. With this sequencing method, approximately 600 - 
900 nucleotides of genomic DNA sequence was obtained.  The sequence consisted of about 
100 nucleotides of a universal flanking sequence (derived from the tetM fragment within IS 
256L), plus unique sequence derived from each gene where Tn4001 was inserted. The unique 
sequence of 1,340 individual clones was evaluated to determine the exact insertion site of 
Tn4001. The insertion site was determined by identifying the nucleotide that matched with 
the very first nucleotide of unique sequence obtained from genomic sequencing. Unique 
sequences were then matched to sequence from the genome of M. bovis PG45 which we 
arbitrarily annotated as described below.  
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Compilation of a mutant library of M. bovis 
 We accessed the complete but un-annotated M. bovis PG45 genome (reported by The 
Institute for Genomic Research in 14 contigs, access date: August, 2007). To arbitrarily 
annotate the PG 45 genome, we grouped all contigs in the order reported, and identified all 
possible open reading frames (ORFs) present (DNAMAN sequence analysis software, 
Lynnon, Quebec). Each ORF was analyzed by comparisons with the recently annotated 
Mycoplasma agalactiae PG2 genome (NC_009497) since this species is phylogenetically 
similar to M. bovis (24). We then identified and assigned the putative function and arbitrary 
position numbers for each ORF of the PG45 genome. Using arbitrarily annotated M. bovis 
PG45 genome, we were able to locate 1,142 distinct Tn 4001 insertion sites from our library. 
We also found that strain PG45 and M23 had many identical ORFs, except for mismatching 
of a few nucleotides on certain ORFs. The mutant library was also used to define the 
essential gene complement of M. bovis by comparison with genome data from other 
mycoplasmas.  
 
Stability of Tn 4001 in transformants 
 To determine the stability of transposon mutants of M. bovis in broth culture, three 
mutants were selected and filter-cloned three times (0.65 µm pore membrane filters). The 
filter-cloned mutants were grown in Friis broth in the absence or presence of 2 µg/ml 
tetracycline for up to 15 passages. At passage number 1, 5, 10, and 15, the cultures were 
harvested and dilution-plated onto Friis agar with or without 2 µg/ml tetracycline. The 
percentage of tetracycline resistant colonies for each mutant at each passage level was 
determined.   
 
Results 
Plasmid pRIT-1 and transformation of M. bovis strain M23 
 Plasmid pRIT-1 was able to transform M. bovis strain M23 with high transformation 
frequency. Initial attempts to transform this organism with pISM2062 using gentamicin 
selection resulted in detection of spontaneous mutants and pseudo-mutants, as reported in the 
earlier study with M. bovis PG45 (3). Unlike gentamicin, tetracycline was able to completely 
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inhibit the growth of M. bovis M23 at the concentration of 2 µg/ml tetracycline, without 
recovery of spontaneous mutants (at detection level limit of 3 x109). Using tetracycline 
selection, we tried to generate mutants using plasmid mini-Tn4001tet, constructed to prevent 
the subsequent transposition of integrated transposon into other sites of the mutant 
chromosome. However, mini-Tn4001tet was unable to create mutants of M. bovis M23, 
consistent with the earlier study using M. bovis PG45 (3). In contrast, and regardless of 
insertion direction of the tetM gene, pRIT-1 was able to confer tetracycline resistance in both 
E. coli and M. bovis M23 and demonstrated high transformation frequency in M. bovis M23. 
Overall transformation frequency ranged from 2 x 10-6 to 5 x10-8 CFU/µg/ml (Figure 2), 
without occurrence of spontaneous mutants. The highest transformation frequency was 
observed when transformation was applied to M. bovis cells harvested at early logarithmic 
phase (8hr) of growth and with 500 ng plasmid DNA. Addition of more than 5 µg of plasmid 
DNA to cells dropped the transformation frequency in all conditions tested (Figure 2). The 
presence of the tetM gene in transformants was confirmed by PCR analysis and one-
directional genomic sequencing of mutants. In addition, filter-cloned mutants were found to 
maintain stable tetracycline resistance when grown in Friis broth without antibiotic pressure 
for up to 15 passages (Figure 3), indicating that instability of transposon insertion in 
transformed cells was not of significant concern with M. bovis strain 23. 
 
Tn4001 insertion site in mutants and genome characterization 
 We identified a total of 663 ORFs on the un-annotated M. bovis PG45 genome, 
covering 89% of the genes reported in M. agalactiae PG2. Since M. bovis and M. agalactiae 
have been considered nearly identical species (24), the anticipated number of ORFs of M. 
bovis would likely be around 742. Of 1,340 mutants subjected by us to insert site sequencing, 
1,142 revealed to have distinctly different insertion sites. The remaining 198 mutants did not 
yield usable insertion site sequence data. Subsequently, 807 out of the 1,142 distinct mutants 
were recognized as having insertions into assigned genes of M. bovis PG45, indicating that 
about 70% of the inserted transposons landed into functional gene regions. The remaining 
335 mutants had inserts in 188 different intergenic regions. However, these 335 intergenic 
insert mutants should be re-analyzed after full annotation of the M. bovis PG45 genome is 
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available. Further analysis revealed that the 807 mutants had inserts in 324 putative genes, 
out of our arbitrarily annotated 663 genes. Since the mutants in this study were selected as 
colonies grown on modified Friis agar plates, these 324 genes that were disrupted by 
transposon insertion are not essential genes for M. bovis. On the opposite, the remaining 339 
genes out of 663, where disruptions were not recovered after analysis of 1,142 transposition 
incidents, are most likely essential genes for M. bovis. In contrast, 382 genes were considered 
to be the essential gene complement for an independently living organism, on the basis of 
global mutagenesis of M. genitalium and M. pneumonia (7, 10, 13). The number of non-
essential genes in M. bovis PG45 might then be 360 genes by subtraction of 382 from the 
anticipated 742 genes. In this library, 1,142 transposition events hit about 90.8% (342/360) of 
the expected non-essential genes of M. bovis PG45, implying that saturation coverage of non-
essential genes of M. bovis was nearly complete.  
 As shown in Supplementary Table 1, proteins of unknown function (hypothetical 
proteins) and transporters were heavily represented among the non-essential genes of M. 
bovis. Disruption of multiple types of transporters was permissive for growth of M. bovis in 
rich media. These transporters included oligopeptide transporters, sugar transporters, glycerol 
transporters, chromate transporter, spermidine/putrescine transporter, and uncharacterized 
transporters. Interestingly, 21 of the genes recognized as non-essential in our library were 
recognized as essential in other mycoplasma species (7, 8, 10, 13). These M. bovis genes are 
listed in Supplementary Table 2, and include genes related to metabolic pathways and some 
genes involved in critical biological functions. A listing of 339 genes that did not disrupted in 
M. bovis is included in Supplementary Table 3. 
 
Discussion 
 Our successful development of a large library of random transposon mutants resulted 
from achieving high efficiencies of transformation, in the range of those reported for M. 
arthritidis and M. pneumonia using pVIT-1 (5). As reported previously (Chopra-Dewastaly 
et al, 2005), a low concentration of plasmid DNA in the transformation reaction was required 
to obtain transformants. In addition, we observed that use of very early log M. bovis cells 
markedly improved transformation efficiency. Finally, the replacement of the gentamicin 
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resistance marker by the tetM tetracycline resistance marker eliminated the problem 
associated with the recovery of large numbers of spontaneous mutants (Chopra-Dewastaly et 
al, 2005). It should be noted that tetracycline resistance is very common among field isolates 
of M. bovis (Rosenbusch et al, 2007); thus, our new strategy can only be applied to a subset 
of strains that are highly susceptible to this antibiotic. Interestingly, attempts to transform M. 
bovis M23 with mini-Tn4001Tet (26), which was able to confer tetracycline resistance to M. 
gallisepticum, were unsuccessful, consistent with a previous report with M. bovis (3). 
Plasmid pRIT-1 construct carrying Tn4001 functionality plus a tetM gene was developed 
using a strategy similar to that used for pIVT-1 construction (5). As in that report, pRIT-1 
conferred tetracycline resistance in both E. coli and M. bovis strain M23 regardless of the 
insert direction of the tetM gene. Importantly, the mutants generated by pRIT-1 stably 
maintained phenotype in liquid medium for more than 15 passages in either presence or 
absence of antibiotic pressure, indicating that instability of transposon insertion in mutants 
was not occurring.  
 A key factor in the establishment of global mutagenesis is to generate enough mutants 
to approach saturation of the entire genome of the recipient host. Sequencing of insertion 
sites in 1,340 mutants allowed us to cover about 90% of the predicted dispensable genes of 
M. bovis, which may be enough to invest this library of mutants in further studies. The 
conception of the minimal gene complement for independent replication of an organism has 
been derived by subtraction of non-essential genes from the entire gene repertoire found in a 
fully sequenced bacterial genome. Approaches to this concept have been made by either in 
silico comparative genomics (9) or global mutagenesis of a microorganism (17, 29, 30). In 
particular, M. genitalium is recognized as the self-replicating microorganism possessing the 
smallest genome, 580kb in size, and the minimal number of genes has been estimated by 
global mutagenesis of this microorganism (7). This minimal genome of 382 genes, deduced 
from the essential genes in M. genitalium is continually reduced in size with data from global 
mutagenesis in other mycoplasma species (6-8, 10, 13). A hypothetical organism with a 
minimal genome would likely be a parasite heavily dependent on its host for the supply of 
metabolites (18). In bacteria with small genomes like the mycoplasma, the majority of genes 
in the minimal set are predicted to be essential, yet may be dispensable in other species with 
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larger genomes because of functional redundancy (18). The minimal genome size required 
for cell survival has been estimated to be about 250 genes in Bacillus subtilis, using global 
mutagenesis (17).  
 The availability of a global mutant library of M. bovis should now make possible 
studies on the biology and pathogenicity of this mycoplasma at the molecular level. In 
conclusion, we demonstrated the reliability of plasmid pRIT-1 to construct a transposon-
based mutant library of M. bovis M23. After arbitrary annotation of the genome of M. bovis 
PG45, analysis of the M23 mutant library allowed the designation of 21 dispensable genes of 
M. bovis that have previously been classified as essential genes in other species of 
mycoplasma.  
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 Figure 1. Construction of pRIT
IS256L arm of Tn4001 and then ligated with 4.98 kb portion derived of HcII
1002. The resulting plasmid is pRIT
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-1. pISM 2062 was linearized at the SmaI site
-1 which confers tetracycline resistance. 
 
 
 in the 
-digested pISM 
 
  
 
 Figure 2. Transformation frequency of pRIT
M. bovis was cultured for designated times
♦500 ng, ■1.0 µg, ▲2.0 µg or 
8-10 hours of culture and transformed with 500
transformation frequency. 
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-1 in Mycoplasma bovis 
, harvested by centrifugation and transformed with 
●5.0 µg of DNA, respectively. Cells that were harvested after 
 ng or 1.0 µg of DNA had the highest 
 
 
 
strain M23. 
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 Figure 3. Transformants retained inserts in absence of selective pressure. 
Mycoplasma bovis strain M23 was cultured in both selective and non-selective Friis broth 
and passed every 24 hours up to 15 passages. Passages 1 to 15 were plated on both ■selective 
and ▲non-selective Friis plates and total colonies counted. Three independent transformants 
were used and the results averaged. Error bars represent the S.E.M.  
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Supplementary table 1. List of genes of Mycoplasma bovis strain M23 disrupted 
by transposon mutagenesis.  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 5 DNA polymerase III, beta chain  MAG_0020 
MBO 6 esterase/lipase  MAG_0030 
MBO 7 NADH dependent flavin oxidoreductase  MAG_0050 
MBO 8 lipoate-protein ligase A, truncated product  MAG_0060 
MBO 9 lipoate-protein ligase A  MAG_0070 
MBO 10 hypothetical protein  MAG_0080 
MBO 11 glycine cleavage system H protein  MAG_0090 
MBO 12 hypothetical protein  MAG_0100 
MBO 13 hypothetical protein  MAG_0110 
MBO 16 ABC transporter, ATP-binding protein, P59  MAG_0140 
MBO 17 sugar ABC transporter permease  MAG_0150 
MBO 21 hypothetical protein  MAG_0190 
MBO 22 hypothetical protein  MAG_0200 
MBO 23 hypothetical protein  MAG_0250 
MBO 26 hypothetical protein  MAG_0280 
MBO 27 ABC transporter ATP-binding protein  MAG_0290 
MBO 30 hypothetical protein  MAG_0330 
MBO 31 oligopeptide ABC transporter, ATP-binding protein (OppF)  MAG_0340 
MBO 32 oligopeptide ABC transporter, ATP-binding protein (OppD)  MAG_0350 
MBO 33 oligopeptide ABC transporter, permease protein(OppC)  MAG_0360 
MBO 34 oligopeptide ABC transporter, permease protein(OppB)  MAG_0370 
MBO 35 oligopeptide ABC transporter, substrate-binding protein (OppA) MAG_0380 
MBO 36 hypothetical protein  MAG_0390 
MBO 38 tRNA/rRNA methyltransferase  MAG_0410 
MBO 39 hypothetical protein  MAG_0420 
MBO 42 hypothetical protein  MAG_0450 
MBO 45 hypothetical protein  MAG_0480 
MBO 46 hypothetical protein  MAG_0490 
MBO 47 glycerol-3-phosphate dehydrogenase  MAG_0500 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 48 dimethyladenosine transferase  MAG_0510 
MBO 49 putative deoxyribonuclease (YabD) deoxyribonuclease (TatD)  MAG_0520 
MBO 54 EpsG  MAG_0570 
MBO 58 lipoate-protein ligase A  MAG_0600 
MBO 60 asparagine synthetase AsnA  MAG_0640 
MBO 67 proline iminopeptidase (Pip)  MAG_0710 
MBO 70 DNA-damage repair protein MucB  MAG_0740 
MBO 71 putative nicotinate-nucleotide adenylyltransferase  MAG_0750 
MBO 72 ribosomal large subunit pseudouridine synthaseB  MAG_0760 
MBO 73 lipoprotein  MAG_0770 
MBO 74 fructose-bisphosphate aldolase (Fba)  MAG_0780 
MBO 75 nuclease  MAG_0790 
MBO 78 hypothetical protein  MAG_0820 
MBO 79 hypothetical protein  MAG_0830 
MBO 80 hypothetical protein  MAG_0840 
MBO 84 hypothetical protein  MAG_0880 
MBO 88 hypothetical protein  MAG_0920 
MBO 94 hypothetical protein  MAG_0980 
MBO 95 hypothetical protein  MAG_0990 
MBO 96 hypothetical protein  MAG_1000 
MBO 97 oligopeptide ABC transporter, permease protein(OppB)  MAG_1010 
MBO 98 oligopeptide ABC transporter system, permease protein (OppC)  MAG_1020 
MBO 99 oligopeptide ABC transporter, ATP-binding protein (OppD)  MAG_1030 
MBO 100 oligopeptide ABC transporter, ATP-binding protein (OppF)  MAG_1040 
MBO 101 lipoprotein  MAG_1050 
MBO 103 hypothetical protein  MAG_1070 
MBO 104 hypothetical protein  MAG_1080 
MBO 105 hypothetical protein  MAG_1100 
MBO 107 hypothetical protein  MAG_1120 
MBO 108 hypothetical protein  MAG_1140 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 112 XAA-Pro aminopeptidase  MAG_1180 
MBO 114 hypothetical protein  MAG_1220 
MBO 115 putative phosphoketolase  MAG_1230 
MBO 116 oligoendopeptidase F  MAG_1240 
MBO 119 spermidine/putrescine ABC transporter permease  MAG_1270 
MBO 122 hypothetical protein  MAG_1300 
MBO 123 thiamine biosynthesis protein thiI  MAG_1310 
MBO 124 hypothetical protein  MAG_1320 
MBO 125 hypothetical protein  MAG_1330 
MBO 126 hypothetical protein  MAG_1340 
MBO 127 hypothetical protein  MAG_1360 
MBO 128 valyl-tRNA synthetase  MAG_1370 
MBO 129 FolD bifunctional protein MAG_1380 
MBO 130 phosphotransacetylase  MAG_1390 
MBO 131 acetate kinase  MAG_1400 
MBO 132 phosphopantetheine adenylyltransferase MAG_1410 
MBO 133 GTPase EngB  MAG_1420 
MBO 134 hypothetical protein  MAG_1430 
MBO 135 pyruvate kinase  MAG_1440 
MBO 136 tRNA (uracil-5-)-methyltransferase Gid  MAG_1470 
MBO 140 hypothetical protein  MAG_1520 
MBO 141 Type III restriction-modification system: methylase  MAG_1530 
MBO 142 trigger factor  MAG_1540 
MBO 143 lipoprotein  MAG_1560 
MBO 144 hypothetical protein  MAG_1570 
MBO 145 hypothetical protein MAG_1580 
MBO 146 hypothetical protein MAG_1590 
MBO 147 hypothetical protein MAG_1600 
MBO 148 hypothetical protein MAG_1610 
MBO 149 hypothetical protein MAG_1620 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 150 integral membrane protein  MAG_1640 
MBO 153 lipoprotein  MAG_5900 
MBO 154 aminopeptidase  MAG_5890 
MBO 155 hypothetical protein  MAG_5870 
MBO 156 hypothetical protein MAG_5880 
MBO 159 hypothetical protein MAG_5840 
MBO 160 acetyltransferase  MAG_5830 
MBO 163 S-adenosylmethionine synthetase  MAG_5800 
MBO 166 lipoprotein  MAG_5770 
MBO 167 hypothetical protein MAG_5760 
MBO 169 
methylase protein of Type I restriction-modification system 
HsdM  MAG_5730 
MBO 170 
methylase protein of Type I restriction-modification-
modification system  MAG_5650 
MBO 171 Type I R/M system specificity subunit  MAG_5640 
MBO 173 hypothetical protein MAG_5700 
MBO 174 hypothetical protein MAG_5710 
MBO 177 hypothetical protein MAG_5620 
MBO 180 heat shock protein GrpE (activation of DnaK)  MAG_5580 
MBO 181 large-conductance mechanosensitive channel  MAG_5570 
MBO 182 hypothetical protein  MAG_5560 
MBO 185 16S rRNA uridine-516 pseudouridylate synthase  MAG_5530 
MBO 186 aminopeptidase  MAG_5520 
MBO 188 recombinase A  MAG_5500 
MBO 189 hypothetical protein  MAG_5480 
MBO 210 hypothetical protein MAG_5280 
MBO 222 hypothetical protein MAG_5150 
MBO 224 deoxyribose-phosphate aldolase  MAG_5130 
MBO 225 thymidine phosphorylase (TDRPASE)  MAG_5120 
MBO 227 hypothetical protein MAG_5100 
MBO 229 lipoprotein  MAG_5080 
MBO 230 ABC transporter permease protein  MAG_5070 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 231 ABC transporter permease protein  MAG_5060 
MBO 232 ABC transporter ATP-binding protein  MAG_5050 
MBO 235 UvrABC system protein C  MAG_5020 
MBO 237 hypothetical protein  MAG_5000 
MBO 238 endonuclease IV  MAG_4990 
MBO 239 hypothetical protein  MAG_4980 
MBO 240 hexosephosphate transport protein  MAG_4970 
MBO 241 hypothetical protein  MAG_4960 
MBO 242 hypothetical protein  MAG_4950 
MBO 243 transmembrane protein  MAG_4940 
MBO 244 acetate kinase (acetokinase)  MAG_4930 
MBO 245 phosphate acetyltransferase(phosphotransacetylase)  MAG_4920 
MBO 246 hypothetical protein  MAG_4910 
MBO 247 L-lactate dehydrogenase (L-LDH)  MAG_4900 
MBO 250 hypothetical protein MAG_4860 
MBO 255 GTP-binding protein LepA  MAG_4810 
MBO 256 hypothetical protein  MAG_4790 
MBO 261 lipoprotein  MAG_4740 
MBO 262 hypothetical protein  MAG_4730 
MBO 263 hypothetical protein  MAG_4720 
MBO 264 hypothetical protein  MAG_4710 
MBO 265 oligopeptide transport system permease protein(OppB)  MAG_4700 
MBO 272 hypothetical protein  MAG_4640 
MBO 273 hypothetical protein  MAG_4630 
MBO 274 hypothetical protein MAG_4620 
MBO 275 ABC transporter, ATP-binding protein  MAG_4610 
MBO 276 ABC transporter, permease protein  MAG_4600 
MBO 277 cation-transporting P-type ATPase  MAG_4590 
MBO 279 30S ribosomal protein S9  MAG_4560 
MBO 282 hypothetical protein MAG_2790 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 284 hypothetical protein  MAG_2810 
MBO 286 putative transmembrane protein  MAG_2830 
MBO 287 hypothetical protein MAG_2840 
MBO 288 putative transmembrane protein  MAG_2860 
MBO 289 putative transmembrane protein  MAG_2850 
MBO 290 hypothetical protein  MAG_2870 
MBO 291 putative transmembrane protein  MAG_2880 
MBO 293 hypothetical protein  MAG_2900 
MBO 294 hypothetical protein  MAG_2910 
MBO 295 putative transmembrane protein  MAG_2920 
MBO 296 F0F1 ATP synthase subunit alpha  MAG_2930 
MBO 297 F0F1 ATP synthase subunit beta  MAG_2940 
MBO 298 lipoprotein  MAG_2950 
MBO 299 hypothetical protein  MAG_2960 
MBO 304 glycosyltransferase  MAG_3010 
MBO 307 hypothetical protein MAG_3040 
MBO 310 Mg2+ transport protein (MGTE)  MAG_3070 
MBO 312 hypothetical protein MAG_3090 
MBO 314 ABC transporter ATP-binding protein  MAG_3110 
MBO 315 hypothetical protein  MAG_3120 
MBO 316 peptide methionine sulfoxide reductase  MAG_3130 
MBO 318 foramidopyrimidine DNA glycosylase  MAG_3150 
MBO 319 glucose-6-phosphate isomerase  MAG_3160 
MBO 320 glucose-6-phosphate isomerase  MAG_3170 
MBO 321 30S ribosomal protein S1  MAG_3180 
MBO 327 hypothetical protein MAG_3240 
MBO 330 hypothetical protein MAG_5660 
MBO 335 P30, lipoprotein  MAG_3470 
MBO 336 hypothetical protein  MAG_3480 
MBO 351 hypothetical protein  MAG_3650 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 354 endopeptidase O  MAG_3680 
MBO 355 hypothetical protein MAG_3690 
MBO 357 cell division protein ftsZ  MAG_3710 
MBO 358 hypothetical protein  MAG_3720 
MBO 363 hypothetical protein  MAG_3770 
MBO 364 excinuclease ABC subunit B  MAG_3780 
MBO 365 excinuclease ABC subunit A  MAG_3790 
MBO 367 hypothetical protein  MAG_3810 
MBO 371 hypothetical protein MAG_3860 
MBO 372 hypothetical protein  MAG_3360 
MBO 373 hypothetical protein MAG_3870 
MBO 374 hypothetical protein MAG_3880 
MBO 375 hypothetical protein MAG_3890 
MBO 376 hypothetical protein MAG_3900 
MBO 378 hypothetical protein  MAG_3920 
MBO 379 hypothetical protein MAG_3930 
MBO 380 hypothetical protein  MAG_3940 
MBO 381 hypothetical protein  MAG_3950 
MBO 382 lipoprotein  MAG_1550 
MBO 383 hypothetical protein MAG_3960 
MBO 388 hypothetical protein MAG_4050 
MBO 389 hypothetical protein MAG_4060 
MBO 390 hypothetical protein  MAG_0230 
MBO 392 oxidoreductase, potentially truncated inN-terminal  MAG_4120 
MBO 393 hypothetical protein MAG_4130 
MBO 394 hypothetical protein  MAG_4140 
MBO 398 purine nucleoside phosphorylase (inosinephosphorylase)  MAG_4180 
MBO 399 hypothetical protein MAG_4220 
MBO 400 hypothetical protein  MAG_4230 
MBO 401 hypothetical protein  MAG_4270 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 402 alcohol dehydrogenase  MAG_4280 
MBO 405 hypothetical protein  MAG_4350 
MBO 406 hydrolase  MAG_4360 
MBO 408 ABC transporter ATP-binding protein  MAG_4380 
MBO 410 putative glycerol-3-phosphate acyltransferase PlsX  MAG_4400 
MBO 411 hypothetical protein  MAG_4410 
MBO 412 hypothetical protein  MAG_4420 
MBO 413 hypothetical protein  MAG_4430 
MBO 416 hypothetical protein  MAG_4460 
MBO 418 glycerol facilitator factor  MAG_4480 
MBO 421 hypothetical protein  MAG_4510 
MBO 423 hypothetical protein  MAG_4530 
MBO 428 alcohol dehydrogenase  MAG_2740 
MBO 434 hypothetical protein  MAG_2680 
MBO 438 hypothetical protein  MAG_2640 
MBO 441 lipoprotein  MAG_2610 
MBO 443 30S ribosomal protein S2  MAG_2590 
MBO 444 hypothetical protein  MAG_2550 
MBO 446 hypothetical protein  MAG_2570 
MBO 447 hypothetical protein  MAG_2580 
MBO 448 lipoprotein  MAG_2540 
MBO 450 lipoprotein  MAG_2520 
MBO 451 lipoprotein  MAG_2510 
MBO 452 hypothetical protein  MAG_2500 
MBO 453 hypothetical protein  MAG_2490 
MBO 454 DNA recombination protein  MAG_2480 
MBO 455 proton/glutamate symporter  MAG_2470 
MBO 456 NADH oxidase (NOXASE)  MAG_2460 
MBO 457 hypothetical protein  MAG_2440 
MBO 458 lipoprotein  MAG_2430 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 459 P40, lipoprotein  MAG_2410 
MBO 461 hemolysin-related protein  MAG_2390 
MBO 465 lipoprotein  MAG_2350 
MBO 466 hypothetical protein  MAG_2340 
MBO 469 glycerol ABC transporter, ATP-binding component  MAG_2310 
MBO 473 hypothetical protein  MAG_2270 
MBO 474 tRNA pseudouridine synthase B  MAG_2260 
MBO 476 Holliday junction DNA helicase B  MAG_2240 
MBO 478 hypothetical protein  MAG_2220 
MBO 481 CTP synthetase  MAG_2190 
MBO 482 hypothetical protein  MAG_2160 
MBO 483 hypothetical protein  MAG_2150 
MBO 485 GTPase EngC  MAG_2130 
MBO 486 Serine/threonine-protein kinase  MAG_2120 
MBO 487 protein phosphatase  MAG_2110 
MBO 492 DNA methylase  MAG_2070 
MBO 499 lipoprotein  MAG_2000 
MBO 500 HIT-like protein (cell cycle regulation)  MAG_1990 
MBO 506 transketolase I  MAG_1930 
MBO 507 ribonuclease  MAG_1920 
MBO 508 hypothetical protein  MAG_1910 
MBO 509 ribose-phosphate pyrophosphokinase  MAG_1870 
MBO 515 hypothetical protein  MAG_1810 
MBO 517 DNA methylase  MAG_1790 
MBO 519 hypothetical protein  MAG_1770 
MBO 522 hypothetical protein  MAG_1730 
MBO 523 hypothetical protein  MAG_1720 
MBO 524 hypothetical protein  MAG_1710 
MBO 525 hypothetical protein  MAG_1690 
MBO 526 hypothetical protein  MAG_1670 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 527 hypothetical protein  MAG_1680 
MBO 529 5'nucleotidase  MAG_5910 
MBO 534 ABC transporter ATP-binding protein  MAG_5960 
MBO 536 ABC transporter, ATP-binding protein  MAG_5990 
MBO 537 ABC transporter, ATP-binding protein  MAG_6000 
MBO 538 aminopeptidase  MAG_6080 
MBO 542 lipoprotein  MAG_6130 
MBO 545 lipoprotein  MAG_6200 
MBO 549 ClpB  MAG_6240 
MBO 553 methionyl-tRNA formyltransferase  MAG_6280 
MBO 554 hypothetical protein  MAG_6290 
MBO 556 transcriptional regulator  MAG_6310 
MBO 557 hypothetical protein  MAG_6320 
MBO 558 L-ribulose-5-phosphate 4-epimerase  MAG_6330 
MBO 559 L-xylulose 5-phosphate 3-epimerase  MAG_6340 
MBO 560 3-keto-L-gulonate-6-phosphate decarboxylase  MAG_6350 
MBO 561 Pentitol phosphotransferase enzyme II, acomponent  MAG_6360 
MBO 562 Pentitol phosphotransferase enzyme II, bcomponent  MAG_6370 
MBO 566 hypothetical protein  MAG_6520 
MBO 567 glycerol ABC transporter, permease component  MAG_6530 
MBO 568 glycerol transporter subunit B  MAG_6540 
MBO 569 hypothetical protein  MAG_6560 
MBO 570 hypothetical protein  MAG_6570 
MBO 573 NH(3)-dependent NAD(+) synthetase  MAG_6600 
MBO 576 putative RNA methyltransferase  MAG_6630 
MBO 582 hypothetical protein  MAG_6690 
MBO 583 ribonuclease H II  MAG_6730 
MBO 585 ribosomal large subunit pseudouridine synthaseD  MAG_6750 
MBO 586 chromate transporter  MAG_6760 
MBO 587 chromate transporter  MAG_6770 
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Supplementary table 1. (continued)  
ORF Putative function of ORF  Homolog in Mycoplasma 
agalactiae PG2 
MBO 588 tRNA (guanine-N(7))-methyltransferase  MAG_6780 
MBO 589 hypothetical protein  MAG_6790 
MBO 592 hypothetical protein  MAG_6830 
MBO 598 hypothetical protein  MAG_6900 
MBO 603 hypothetical protein  MAG_6950 
MBO 609 thymidine kinase  MAG_7010 
MBO 611 hypothetical protein  MAG_7030 
MBO 614 Variable surface protein K 
MBO 616 Variable surface protein B 
MBO 617 Variable surface protein G 
MBO 618 Variable surface protein N 
MBO 620 Variable surface protein H 
MBO 626 Variable surface protein O 
MBO 627 Variable surface protein I 
MBO 630 integrase-recombinase  MAG_7110 
MBO 631 hypothetical protein  MAG_7120 
MBO 632 hypothetical protein  MAG_7140 
MBO 642 cytidylate kinase (CK)  MAG_7250 
MBO 643 hypothetical protein  MAG_7260 
MBO 647 hypothetical protein  MAG_7310 
MBO 648 hypothetical protein  MAG_7320 
MBO 649 Acyl carrier protein  MAG_7330 
MBO 650 protoporphirogen oxidase HEMK  MAG_7340 
MBO 657 hypothetical protein  MAG_7410 
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Supplementary table 2. Selected dispensable genes of Mycoplasma bovis strain 
M23 which has been classified previously as essential genes in other mycoplasma 
species.  
Mutant name  Putative function of disrupted genes 
Mycoplasma species where the gene was 
found as essential 
M.bov M.gen M.pul M. arth 
MBO 5 DNA polymerase III, beta chain  - + + + 
MBO 71 
putative nicotinate-nucleotide 
adenylyltransferase  - + + + 
MBO 129 FolD bifunctional protein - + + + 
MBO 131 acetate kinase  - + + + 
MBO 135 pyruvate kinase  - + + + 
MBO 163 S-adenosylmethionine synthetase  - + + + 
MBO 180 heat shock protein GrpE (activation of DnaK)  - + + + 
MBO 224 deoxyribose-phosphate aldolase  - + + + 
MBO 279 30S ribosomal protein S9  - + + + 
MBO 319 glucose-6-phosphate isomerase  - + + + 
MBO 357 cell division protein ftsZ  - + + + 
MBO 410 
putative glycerol-3-phosphate acyltransferase 
PlsX  - + + + 
MBO 443 30S ribosomal protein S2  - + + + 
MBO 456 NADH oxidase (NOXASE)  - + + + 
MBO 486 Serine/threonine-protein kinase  - + + + 
MBO 487 protein phosphatase  - + + + 
MBO 509 ribose-phosphate pyrophosphokinase  - + + + 
MBO 573 NH(3)-dependent NAD(+) synthetase  - + + + 
MBO 642 cytidylate kinase (CK)  - + + + 
MBO 649 Acyl carrier protein  - + + + 
MBO 650 protoporphirogen oxidase HEMK  - + + + 
 
-: those that were found as non-essential genes in M. bovis 
+: those that have been classified previously as essential genes in other mycoplasma 
species 
 
  
 64 
 
Supplementary table 3. List of genes of Mycoplasma bovis strain M23 where insertional 
mutation was not detected. 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 1 hypothetical protein  MAG_1880 
MBO 2 hypothetical protein  MAG_3980 
MBO 3 lipoprotein  MAG_3970 
MBO 4 chromosomal replication initiation protein  MAG_0010 
MBO 14 P48, lipoprotein  MAG_0120 
MBO 15 hypothetical protein  MAG_0130 
MBO 18 sugar ABC transporter permease protein  MAG_0160 
MBO 19 deoxyguanosine kinase  MAG_0170 
MBO 20 deoxyguanosine kinase  MAG_0180 
MBO 24 hypothetical protein  MAG_0260 
MBO 25 HAD superfamily hydrolase  MAG_0270 
MBO 28 hypothetical protein  MAG_0300 
MBO 29 hypothetical protein  MAG_0320 
MBO 37 cysteinyl-tRNA synthetase MAG_0400 
MBO 40 50S ribosomal protein L33  MAG_0430 
MBO 41 transcription antitermination protein NusG  MAG_0440 
MBO 43 uridylate kinase  MAG_0460 
MBO 44 ribosome recycling factor (ribosome releasing factor)  MAG_0470 
MBO 50 tRNA modification GTPase TrmE  MAG_0530 
MBO 51 hypothetical protein  MAG_0540 
MBO 52 glyceraldehyde 3-phosphate dehydrogenase (GAPDH)  MAG_0550 
MBO 53 seryl-tRNA synthetase  MAG_0560 
MBO 55 50S ribosomal protein L34  MAG_7500 
MBO 56 ribonuclease P protein component  MAG_0580 
MBO 57 
putative inner membrane protein translocase component 
YidC  MAG_0590 
MBO 59 esterase/lipase  MAG_0610 
MBO 61 DNA polymerase III PolC  MAG_0650 
MBO 62 recombination factor protein RarA  MAG_0660 
MBO 63 phenylalanyl-tRNA synthetase subunit alpha  MAG_0670 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 64 Uracil-DNA glycosylase (Ung)  MAG_0680 
MBO 65 phenylalanyl-tRNA synthetase beta chain (PheT)  MAG_0690 
MBO 66 serine hydroxymethyltransferase  MAG_0700 
MBO 68 nitrogen fixation protein NifS  MAG_0720 
MBO 69 nitrogen fixation protein NifU  MAG_0730 
MBO 76 50S ribosomal protein L11  MAG_0800 
MBO 77 50S ribosomal protein L1  MAG_0810 
MBO 81 tRNA/rRNA methyltransferase  MAG_0850 
MBO 82 rRNA methylase  MAG_0860 
MBO 83 ribosomal biogenesis GTPase  MAG_0870 
MBO 85 HPr kinase/phosphorylase  MAG_0890 
MBO 86 prolipoprotein diacylglyceryl transferase  MAG_0900 
MBO 87 thioredoxin reductase  MAG_0910 
MBO 89 pyruvate dehydrogenase E1 component, alpha subunit  MAG_0930 
MBO 90 pyruvate dehydrogenase E1 component, beta subunit  MAG_0940 
MBO 91 
dihydrolipoamide acetyltransferase component of pyruvate 
dehydrogenase MAG_0950 
MBO 92 
dihydrolipoamide dehydrogenase (E3 component of 
pyruvate complex)  MAG_0960 
MBO 93 50S ribosomal protein L28  MAG_0970 
MBO 102 hypothetical protein  MAG_1060 
MBO 106 ribose-5-phosphate isomerase B  MAG_1110 
MBO 109 hypothetical protein  MAG_1150 
MBO 110 cytidine deaminase (cytidine aminohydrolase)  MAG_1160 
MBO 111 GTP-binding protein Era  MAG_1170 
MBO 113 prolyl-tRNA synthetase  MAG_1190 
MBO 117 spermidine/putrescine ABC transporter ATP-binding protein  MAG_1250 
MBO 118 spermidine/putrescine ABC transporter permease  MAG_1260 
MBO 120 hypothetical protein  MAG_1280 
MBO 121 50S ribosomal protein L32  MAG_1290 
MBO 137 hypothetical protein  MAG_1480 
MBO 138 D-lactate dehydrogenase  MAG_1490 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 139 esterase/lipase  MAG_1500 
MBO 151 DNA polymerase I  MAG_1650 
MBO 152 putative prophage protein (ps3)  MAG_6440 
MBO 157 phosphoglycerate kinase  MAG_5860 
MBO 158 nicotinate phosphoribosyltransferase  MAG_5850 
MBO 161 Signal recognition particle protein  MAG_5820 
MBO 162 hypothetical protein  MAG_5810 
MBO 164 hypothetical protein  MAG_5790 
MBO 165 glutamyl-tRNA synthetase  MAG_5780 
MBO 168 5-formyltetrahydrofolate cyclo-ligase  MAG_5750 
MBO 172 restriction modification system specificity subunit HsdS  MAG_5720 
MBO 175 Phage family integrase  MAG_5690 
MBO 176 DNA gyrase subunit A  MAG_5630 
MBO 178 30S ribosomal protein S4  MAG_5610 
MBO 179 heat-inducible transcription repressor  MAG_5590 
MBO 183 50S ribosomal protein L21  MAG_5550 
MBO 184 50S ribosomal protein L27  MAG_5540 
MBO 187 hypothetical protein  MAG_5510 
MBO 190 hypothetical protein  MAG_5490 
MBO 191 30S ribosomal protein S10  MAG_5470 
MBO 192 50S ribosomal protein L3  MAG_5460 
MBO 193 50S ribosomal protein L4  MAG_5450 
MBO 194 50S ribosomal protein L23  MAG_5440 
MBO 195 50S ribosomal protein L2  MAG_5430 
MBO 196 30S ribosomal protein S19  MAG_5420 
MBO 197 50S ribosomal protein L22  MAG_5410 
MBO 198 30S ribosomal protein S3  MAG_5400 
MBO 199 50S ribosomal protein L16  MAG_5390 
MBO 200 30S ribosomal protein S17  MAG_5380 
MBO 201 50S ribosomal protein L14  MAG_5370 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 202 50S ribosomal protein L24  MAG_5360 
MBO 203 50S ribosomal protein L5  MAG_5350 
MBO 204 30S ribosomal protein S14  MAG_5340 
MBO 205 30S ribosomal protein S8  MAG_5330 
MBO 206 50S ribosomal protein L6  MAG_5320 
MBO 207 50S ribosomal protein L18  MAG_5310 
MBO 208 30S ribosomal protein S5  MAG_5300 
MBO 209 50S ribosomal protein L15  MAG_5290 
MBO 211 preprotein translocase subunit SecY  MAG_5260 
MBO 212 adenylate kinase  MAG_5250 
MBO 213 methionine aminopeptidase  MAG_5240 
MBO 214 translation initiation factor IF-1  MAG_5230 
MBO 215 30S ribosomal protein S13  MAG_5220 
MBO 216 30S ribosomal protein S11  MAG_5210 
MBO 217 DNA-directed RNA polymerase subunit alpha  MAG_5200 
MBO 218 50S ribosomal protein L17  MAG_5190 
MBO 219 cobalt transporter ATP-binding subunit  MAG_5180 
MBO 220 ABC transporter permease protein  MAG_5160 
MBO 221 cobalt transporter ATP-binding subunit  MAG_5170 
MBO 223 triosephosphate isomerase  MAG_5140 
MBO 226 purine nucleoside phosphorylase (inosinephosphorylase)  MAG_5110 
MBO 228 GTPase ObgE  MAG_5090 
MBO 233 hypothetical protein  MAG_5040 
MBO 234 P80, lipoprotein  MAG_5030 
MBO 236 thioredoxin (TRX)  MAG_5010 
MBO 248 malate permease  MAG_4890 
MBO 249 arginyl-tRNA synthetase  MAG_4880 
MBO 251 hypothetical protein  MAG_4840 
MBO 252 hypothetical protein  MAG_4850 
MBO 253 NADPH flavin oxidoreductase  MAG_4830 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 254 hypothetical protein  MAG_4820 
MBO 257 ATP-binding protein  MAG_4780 
MBO 258 50S ribosomal protein L20  MAG_4770 
MBO 259 50S ribosomal protein L35  MAG_4760 
MBO 260 translation initiation factor IF-3  MAG_4750 
MBO 266 phosphocarrier protein HPr(histidine-containing protein)  MAG_4690 
MBO 267 Acyl carrier protein phosphodiesterase  MAG_4680 
MBO 268 transcription termination factor (NusB)  MAG_4670 
MBO 269 hypothetical protein  MAG_4660 
MBO 270 phosphomannomutase  MAG_4650 
MBO 271 UTP-glucose-1-phosphate uridyltransferase  MAG_4580 
MBO 278 hypothetical protein  MAG_4570 
MBO 280 50S ribosomal protein L13  MAG_4550 
MBO 281 hypothetical protein MAG_4540 
MBO 285 DNA ligase  MAG_2820 
MBO 292 hypothetical protein  MAG_2890 
MBO 300 hypothetical protein  MAG_2970 
MBO 301 hypothetical protein  MAG_2980 
MBO 302 ATP-dependent helicase  MAG_2990 
MBO 303 hypothetical protein  MAG_3000 
MBO 305 asparaginyl-tRNA synthetase  MAG_3020 
MBO 306 hypothetical protein  MAG_3030 
MBO 308 hypothetical protein  MAG_3050 
MBO 309 hypothetical protein  MAG_3060 
MBO 311 elongation factor P  MAG_3080 
MBO 313 ABC transporter ATP-binding protein  MAG_3100 
MBO 317 hypothetical protein  MAG_3140 
MBO 322 phosphopyruvate hydratase  MAG_3190 
MBO 323 elongation factor Tu  MAG_3200 
MBO 324 hypothetical protein  MAG_3210 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 325 hypothetical protein  MAG_3220 
MBO 326 O-sialoglycoprotein endopeptidase  MAG_3230 
MBO 328 hypothetical protein  MAG_3320 
MBO 329 hypothetical protein  MAG_3250 
MBO 331 hypothetical protein  MAG_5670 
MBO 332 tryptophanyl-tRNA synthetase  MAG_3430 
MBO 333 threonyl-tRNA synthetase  MAG_3440 
MBO 334 hypothetical protein  MAG_3450 
MBO 337 hypothetical protein  MAG_3490 
MBO 338 F0F1 ATP synthase subunit A  MAG_3500 
MBO 339 ATP synthase C chain  MAG_3510 
MBO 340 ATP synthase B chain  MAG_3520 
MBO 341 ATP synthase delta subunit  MAG_3530 
MBO 342 F0F1 ATP synthase subunit alpha  MAG_3540 
MBO 343 F0F1 ATP synthase subunit gamma  MAG_3550 
MBO 344 F0F1 ATP synthase subunit beta  MAG_3560 
MBO 345 ATP synthase epsilon chain  MAG_3570 
MBO 346 hypothetical protein  MAG_3580 
MBO 347 hypothetical protein  MAG_3610 
MBO 348 hypothetical protein  MAG_3620 
MBO 349 heat shock ATP-dependent protease  MAG_3630 
MBO 350 leucyl-tRNA synthetase (leucine-tRNA ligase)  MAG_3640 
MBO 352 Uracil phosphoribosyltransferase  MAG_3660 
MBO 353 single-strand binding protein(helix-destabilizing protein)  MAG_3670 
MBO 356 glycine cleavage system H protein  MAG_3700 
MBO 359 S-adenosyl-methyltransferase  MAG_3730 
MBO 360 cell division protein MraZ  MAG_3740 
MBO 361 potassium uptake protein KtrA  MAG_3750 
MBO 362 potassium uptake protein KtrB  MAG_3760 
MBO 366 hypothetical protein  MAG_3800 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 368 translation-associated GTPase  MAG_3820 
MBO 369 hypoxanthine-guanine phosphoribosyltransferase(HGPRT)  MAG_3840 
MBO 370 transcription elongation factor greA  MAG_3850 
MBO 377 hypothetical protein  MAG_3910 
MBO 384 hypothetical protein  MAG_3990 
MBO 385 hypothetical protein  MAG_4000 
MBO 386 hypothetical protein  MAG_4020 
MBO 387 hypothetical protein  MAG_4040 
MBO 391 lipoprotein  MAG_4320 
MBO 395 putative Holliday junction resolvase  MAG_4150 
MBO 396 alanyl-tRNA synthetase  MAG_4160 
MBO 397 
tRNA (5-methylaminomethyl-2-thiouridylate)-
methyltransferase  MAG_4170 
MBO 403 lipoprotein  MAG_4330 
MBO 404 alcohol dehydrogenase  MAG_4340 
MBO 407 ABC transporter permease protein  MAG_4370 
MBO 409 ribonuclease III (RNase III)  MAG_4390 
MBO 414 hypothetical protein  MAG_4440 
MBO 415 hypothetical protein  MAG_4450 
MBO 417 glycerol kinase  MAG_4470 
MBO 419 aspartyl-tRNA synthetase (AspRS)  MAG_4490 
MBO 420 histidyl-tRNA synthetase (HisRS)  MAG_4500 
MBO 422 hypothetical protein  MAG_4520 
MBO 424 30S ribosomal protein S18  MAG_2780 
MBO 425 single-stranded DNA-binding protein  MAG_2770 
MBO 426 30S ribosomal protein S6  MAG_2760 
MBO 427 DNA topoisomerase I  MAG_2750 
MBO 429 preprotein translocase subunit SecA  MAG_2730 
MBO 430 hypothetical protein  MAG_2720 
MBO 431 alkylphosphonate ABC transporter permease  MAG_2710 
MBO 432 ABC transporter, ATP-binding protein  MAG_2700 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 433 alkylphosphonate ABC transporter substrate-binding protein  MAG_2690 
MBO 435 glycyl-tRNA synthetase  MAG_2670 
MBO 436 DNA primase  MAG_2660 
MBO 437 RNA polymerase sigma factor  MAG_2650 
MBO 439 NADH oxidase (NOXASE)  MAG_2630 
MBO 440 hypothetical protein  MAG_2620 
MBO 442 elongation factor Ts (EF-Ts)  MAG_2600 
MBO 445 hypothetical protein  MAG_2560 
MBO 449 hypothetical protein  MAG_2530 
MBO 460 lipoprotein  MAG_2400 
MBO 462 replicative DNA helicase  MAG_2380 
MBO 463 50S ribosomal protein L9  MAG_2370 
MBO 464 hypothetical protein  MAG_2360 
MBO 467 glycerol ABC transporter, permease component  MAG_2330 
MBO 468 glycerol ABC transporter, permease component  MAG_2320 
MBO 470 esterase/lipase  MAG_2300 
MBO 471 30S ribosomal protein S15  MAG_2290 
MBO 472 hypothetical protein  MAG_2280 
MBO 475 protein-export membrane protein  MAG_2250 
MBO 477 Holliday junction DNA helicase motor protein  MAG_2230 
MBO 479 lipoprotein signal peptidase (SPase II)  MAG_2210 
MBO 480 isoleucyl-tRNA synthetase  MAG_2200 
MBO 484 ribulose-phosphate 3-epimerase  MAG_2140 
MBO 488 guanylate kinase  MAG_2100 
MBO 490 hypothetical protein  MAG_2090 
MBO 491 ribonuclease R  MAG_2080 
MBO 493 methionyl-tRNA synthetase  MAG_2060 
MBO 494 hypothetical protein  MAG_2050 
MBO 495 cell division protein FtsY  MAG_2040 
MBO 496 hypothetical protein  MAG_2030 
  
 72 
 
Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 497 Thiol peroxidase  MAG_2020 
MBO 498 50S ribosomal protein L33  MAG_2010 
MBO 501 lipoprotein  MAG_1980 
MBO 502 hypothetical protein  MAG_1970 
MBO 503 hypothetical protein  MAG_1960 
MBO 504 30S ribosomal protein S20  MAG_1950 
MBO 505 inorganic pyrophosphatase  MAG_1940 
MBO 510 methyltransferase GidB (glucose inhibiteddivision protein B)  MAG_1860 
MBO 511 ribonuclease HII (RNase HII)  MAG_1850 
MBO 512 hypothetical protein  MAG_1840 
MBO 513 DNA topoisomerase IV subunit A  MAG_1830 
MBO 514 topoisomerase IV subunit B  MAG_1820 
MBO 516 formylmethionine deformylase  MAG_1800 
MBO 518 hypothetical protein  MAG_1780 
MBO 520 hypothetical protein  MAG_1750 
MBO 521 
tRNA uridine 5-carboxymethylaminomethyl modification 
enzyme MAG_1740 
MBO 528 DNA polymerase III DnaE  MAG_1660 
MBO 530 elongation factor G  MAG_5920 
MBO 531 30S ribosomal protein S7  MAG_5930 
MBO 532 30S ribosomal protein S12  MAG_5940 
MBO 533 hypothetical protein  MAG_5950 
MBO 535 hypothetical protein  MAG_6150 
MBO 539 hypothetical protein  MAG_6100 
MBO 540 DNA-directed RNA polymerase subunit beta'  MAG_6110 
MBO 541 DNA-directed RNA polymerase subunit beta  MAG_6120 
MBO 543 50S ribosomal protein L7/L12  MAG_6180 
MBO 544 50S ribosomal protein L10  MAG_6190 
MBO 546 lysyl-tRNA synthetase  MAG_6210 
MBO 547 hypothetical protein  MAG_6220 
MBO 548 hypothetical protein  MAG_6230 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 550 30S ribosomal protein S16  MAG_6250 
MBO 551 tRNA (guanine-N(1)-)-methyltransferase  MAG_6260 
MBO 552 50S ribosomal protein L19  MAG_6270 
MBO 555 phosphoenolpyruvate-protein phosphotransferase  MAG_6300 
MBO 563 ascorbate-specific PTS system enzyme IIC  MAG_6380 
MBO 564 hypothetical protein  MAG_6390 
MBO 565 hypothetical protein  MAG_6400 
MBO 571 hypothetical protein  MAG_6580 
MBO 572 hypothetical protein  MAG_6590 
MBO 574 ICEF-IA ORF9 ortholog  MAG_6610 
MBO 575 esterase/lipase  MAG_6620 
MBO 577 putative DNA helicase  MAG_6640 
MBO 578 hypothetical protein  MAG_6650 
MBO 579 hypothetical protein  MAG_6660 
MBO 580 hypothetical protein  MAG_6670 
MBO 581 modification methylase  MAG_6680 
MBO 584 hypothetical protein  MAG_6740 
MBO 590 hypothetical protein  MAG_6800 
MBO 591 hypothetical protein  MAG_6810 
MBO 593 DNA polymerase III subunit delta'  MAG_6840 
MBO 594 thymidylate kinase  MAG_6850 
MBO 595 recombination protein RecR  MAG_6860 
MBO 596 DNA polymerase III subunit gamma and tau  MAG_6870 
MBO 597 phosphoglyceromutase  MAG_6890 
MBO 599 hypothetical protein  MAG_6910 
MBO 600 hypothetical protein  MAG_6920 
MBO 601 
CDP-diacylglycerol-glycerol-3-phosphate3-
phosphatidyltransferase  MAG_6930 
MBO 602 phosphatidate cytidylyltransferase  MAG_6940 
MBO 604 adenine phosphoribosyltransferase  MAG_6960 
MBO 605 translation initiation factor IF-2  MAG_6970 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 606 hypothetical protein  MAG_6980 
MBO 607 transcription elongation factor NusA  MAG_6990 
MBO 608 hypothetical protein  MAG_7000 
MBO 610 aminopeptidase (leucine aminopeptidase)  MAG_7020 
MBO 612 Open reading frame 5 
MBO 613 Variable surface protein L 
MBO 615 Variable surface protein M 
MBO 619 Variable surface protein A 
MBO 621 Open reading frame 4 
MBO 622 Open reading frame 3 
MBO 623 Variable surface frame J 
MBO 624 Open reading frame 2 
MBO 625 Variable surface protein F 
MBO 628 Variable surface protein E 
MBO 629 site-specific tyrosine recombinase  
MBO 633 aspartyl/glutamyl-tRNA amidotransferase subunit B  MAG_7160 
MBO 634 amidase  MAG_7170 
MBO 635 hypothetical protein  MAG_7180 
MBO 636 ribosomal large subunit pseudouridine synthaseC  MAG_7190 
MBO 637 segregation and condensation protein B  MAG_7200 
MBO 638 segregation and condensation protein A  MAG_7210 
MBO 639 1-acyl-SN-glycerol-3-phosphate acyltransferase  MAG_7220 
MBO 640 
Holo-[acyl-carrier protein] synthase 
MAG_7230 
MBO 641 GTP-binding protein EngA  MAG_7240 
MBO 644 heat shock protein DNAJ (activation of DNAK)  MAG_7280 
MBO 645 ribosome-binding factor A  MAG_7290 
MBO 646 tyrosyl-tRNA synthetase 1  MAG_7300 
MBO 651 peptide chain release factor 1  MAG_7350 
MBO 652 hypothetical protein MAG_7360  MAG_7360 
MBO 653 DNA gyrase subunit B  MAG_7370 
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Supplementary table 3. (continued) 
ORF Putative function of ORF Homolog in Mycoplasma 
agalactiae PG2 
MBO 654 thioredoxin  MAG_7380 
MBO 655 SsrA-binding protein  MAG_7390 
MBO 656 hypothetical protein  MAG_7400 
MBO 658 cation-transporting P-ATPase  MAG_7420 
MBO 659 ABC transporter ATP-binding protein  MAG_7430 
MBO 660 ABC transporter permease protein  MAG_7440 
MBO 661 cell division protein ftsH-like protein  MAG_7450 
MBO 662 hypothetical protein  MAG_7460 
MBO 663 peptidyl-tRNA hydrolase  MAG_7470 
MBO 664 exodeoxyribonuclease V alpha chain  MAG_7480 
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CHAPTER 3.  CHARACTERIZATION OF AN ATP-BINDING CASSETTE 
TRANSPORT SYSTEM RESPONSIBLE FOR 
NUCLEOSIDE UPTAKE IN MYCOPLASMA BOVIS STRAIN M23 
 
Abstract 
Mycoplasma bovis transposon mutants defective in the components of a putative 
thymidine transport system were isolated and utilized to characterize the molecular 
mechanism of thymidine transport in M. bovis. Genetic analysis revealed that the transporter 
belongs to a family of classical ABC transport systems and is composed of a substrate 
binding protein (uptB), an ATP-binding cytoplasmic domain (uptA), and integral membrane 
permease proteins (uptC and uptD). Inactivation of each gene of the transporter resulted in 
loss of thymidine uptake, indicating that all components were absolutely required for the 
transport function. The loss of thymidine uptake in these mutants was recovered once the 
intact uptBACD gene cluster was introduced into the mutants. The entry of 3H-thymidine into 
M. bovis mediated by UptBACD was a high-affinity dependent process, with Km of 0.96 ± 
0.7 nM, and Vmax of 244 ± 6.76 nM under the test conditions. Depletion of ATP in 
mycoplasma reduced the level of 3H-thymidine uptake, indicating that the transport system 
was energy-dependent. 3H-thymidine uptake was nearly abolished in the presence of 40-fold 
excess of unlabeled thymidine and reduced in the presence of nucleosides, except 
deoxycytidine. However, nucleobases and pentoses did not affect of 3H-thymidine uptake. 
Thus, the UptBACD transporter of M. bovis possesses specific and high-affinity nucleoside 
transport activity. The activity is likely critical for replication of M. bovis in the host. 
 
Introduction 
Mollicutes are bacteria that are characterized as the smallest and simplest prokaryotes 
capable of autonomous self-replication (29, 31). Because of their small genome capacity, 
Mollicutes have limited synthetic potential for biological substances essential for survival, 
including amino acids, vitamins, fatty acids, and nucleotide precursors (29). They require 
rich nutrients for growth in artificial medium, such as animal sera, and yeast extract (16). In 
particular, nucleotide precursors are among the nutrients that are essential building blocks for 
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the synthesis of genetic materials in all living organisms, including Mollicutes. However, 
most Mollicutes are unable to synthesize de novo purine and pyrimidine bases, and 
subsequently must acquire such molecules from the environment (7, 30). In Mollicutes, the 
requirement of nucleobases for nucleotide synthesis has been reported in several species of 
mycoplasma (14, 18-20, 34, 39). Incorporation of all nucleosides has been demonstrated in 
various species of mycoplasma, including Mycoplasma putrefaciens, Mycoplasma 
gallisepticum, Mycoplasma pneumonia, and Acholeplasma laidlawii (5, 14). In addition, 
rapid uptake of (deoxy)ribonucleoside-5-monophosphate was demonstrated in M. mycoides 
subsp. mycoides by substrate uptake analysis (20, 21). These results supported the potential 
existence of transport systems involved in nucleoside uptake in Mollicutes. Recent 
knowledge gleaned from advances in complete genome sequencing of several Mollicutes 
indicate that about 10 % of the open reading frames in genomes of Mollicutes are devoted to 
encoding for membrane-associated transport systems, with the number of transport systems 
in the range of 55 to 103 per genome (24, 32, 41). Nucleotide precursors might be imported 
via one of these transport systems because Mollicutes are defective in biosynthetic pathways 
for nucleotides (26). In addition to uptake systems, multiple proteins that potentially 
participate in a salvage pathway for utilization of nucleotide precursors have been identified 
in Mollicutes (20, 37). These results strongly suggest that active transport systems capable of 
transporting nucleotide precursors must exist in Mollicutes, and the incorporated substrates 
then can be utilized by the salvage pathways. Despite multiple circumstantial evidence, no 
such transport system responsible for the uptake of nucleotide precursors has been 
characterized in Mollicutes. ABC transport systems are members of a protein family that is 
ubiquitously found in living organisms. They are composed of three main components 
including a substrate-binding protein, an ATP-binding domain, and integral transmembrane 
permeases. These transporter systems are involved in various biological functions in bacteria, 
as either importers or exporters. In Gram-positive bacteria, one of the major roles of ABC 
transport systems is to import nutrient substrates from the environment. This should be a vital 
function in Mollicutes since they need to uptake many nutrients for their survival. In 
Streptococcus mutans, an ABC transport system has recently been characterized as a 
nucleoside transport system (38). Interestingly, several sets of conserved ABC transport 
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systems have been identified in the genomes of Mollicutes, although their biological 
functions have not been characterized. In this study, we have identified mutants defective in 
transporting thymidine in the bovine M. bovis strain M23. Genetic analysis revealed that the 
mutants were disrupted in the genes encoding a putative sugar ABC transport system in M. 
bovis. We report that M. bovis possesses a substrate-binding protein-dependent ABC 
transport system responsible for nucleoside uptake. In addition, all components of the 
transport system are absolutely required for its biological function.  
 
Materials and Methods 
Bacteria, mycoplasma, and growth conditions 
 M. bovis M23 was used as a parent strain for transposon mutant construction and as a 
wild-type for all assays. This is a pathogenic strain of M. bovis isolated from a case of bovine 
pneumonia (28). All mycoplasma strains used are listed in Table 1. Primer sequences used 
are listed in Table 2. All mycoplasma strains were maintained in modified Friis broth 
supplemented with 20% fetal bovine serum (10), and chloramphenicol (25 µg/ml) or 
tetracycline (4 µg/ml) was added to this medium as required. Escherichia coli DH5α was 
used for plasmid manipulation and propagation, and was maintained in Luria-Bertani (LB) 
broth or plates. For E. coli, ampicillin (50 µg/ml), chloramphenicol (25 µg/ml), or 
tetracycline (5 µg/ml) was added to the medium as required.   
 
Chemicals 
 Adenine, guanine, cytosine, uracil, thymine, adenosine, guanosine, uridine, cytidine, 
deoxyadenosine, deoxyguanosine, thymidine, deoxycytidine, deoxyuridine, ribose, 
deoxyribose, arabinose, xylose, valinomycin, sodium orthovandate, 
dicylohexylcarbondiimide (DCC), and 5-bromo-2’-deoxyuridine were purchased from 
Sigma-Aldrich (St. Louis, MO). Gemcitabine was purchased from ChemieTek (Indianapolis, 
IN). 3H-methyl-thymidine (86 Ci/mM) was obtained from GE HealthCare (Piscataway, NJ). 
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Plasmid construction and random mutation 
All genetic manipulation procedures were performed by standard molecular 
techniques (35). The transposon-based plasmid pRIT-1 carrying modified Tn4001 
functionality and tetracycline resistance was constructed and used for the generation of 
isogenic mutants (Lee and Rosenbusch, unpublished data). Briefly, plasmid pISM 2062 (9) 
was digested with SmaI and ligated with 4.98 kb HicII fragment derived from plasmid pISM 
1002 carrying Tn 916 (12), resulting in pRIT-1. For complementation assays, plasmids were 
constructed as follows. The promoter region of the tetM gene conferring tetracycline 
resistance was amplified by PCR on template DNA of pISM1002 using a primer set (TpF, 
TpR) and ligated to SalI-BamHI-digested pUC19, resulting in pRIC-1. The chloramphenicol 
acetyltransferase (cat) gene conferring chloramphenicol resistance was amplified by PCR on 
template DNA of pBR328 (ATCC 37517) using a primer set (CmF, CmR) and inserted into 
MfeI/SmaI-digested plasmid pRI-1, resulting in pRIC-2. The cat gene under control of the 
tetM promoter was amplified by PCR on template DNA of pRIC-2 using a primer set (catF, 
catR) and inserted into SmaI-digested pISM 2062, resulting in pRIC-3. Then, the entire gene 
region encoding the transporter system was amplified by PCR on template DNA of M. bovis 
M23 using a primer set (ABC-F, ABC-R), SmaI-digested, and ligated to SmaI-digested 
pRIC-3, resulted in pRIC-ABC. Plasmid pRIC-ABC carries both the entire region of the 
uptBACD encoding ABC transporter and the cat gene within the modified Tn 4001. 
Mycoplasma transformation was performed as described previously (27). Isogenic mutants 
were selected on Friis plates with 2 µg/ml tetracycline, whereas the complemented strains 
were selected on Friis plates with 25 µg/ml chloramphenicol. The selected mutants were 
filter-cloned and stored at -70˚C until used.  
 
Mutant selection 
A mutant (MBOTn 2627) that was defective in thymidine uptake was obtained from a 
library of transposon mutants (Lee and Rosenbusch, unpublished data) after screening with a 
thymidine uptake assay. The mutant completely lost its ability to incorporate thymidine, 
when compared to the wild type strain M23 of M. bovis. To identify the gene responsible for 
this functional loss, the transposon insertion site in the mutant was evaluated by one-
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directional genomic sequencing using a primer (5’-CGAGGGATTCCGAGGACTG-3’) 
positioned outwards on the IS256L sequence of Tn4001. The disrupted gene in MBOTn 2627 
was identified as the ATP-binding domain protein of a putative sugar ABC transporter, 
located in an arbitrary annotation of the genome of M. bovis strain PG45 (Lee and 
Rosenbusch, unpublished data). Genomic analysis of flanking genes and their putative 
translation products revealed that the gene was a component of a putative ABC transporter 
system composed of four functional genes, consisting of a substrate binding protein, an ATP-
binding domain protein, and two different integral transmembrane domain proteins. Three 
additional mutants, MBO 3754, MBO 2927, and MBO 3178, with disruptions in each one of 
the other 3 genes of the transporter were also found in the library.  
 
Nucleotide sequence of the ABC transporter of M. bovis M23 
 To determine the nucleotide sequence of the ABC transporter of M. bovis M23, total 
genomic DNA was extracted and subjected to Iowa State University DNA facility. The entire 
nucleotide sequence of the ABC transporter was obtained by a “primer walk” strategy on 
M23 genomic DNA.  
 
Thymidine uptake assay 
Thymidine uptake was determined by a rapid filtration method (21), modified as 
follows. Cells growing exponentially in Friis medium (16 hours at 37 °C) were diluted 1:10 
into pre-warmed medium and further incubated for 4 hrs. Cells were harvested by 
centrifugation (8,000x g, 4˚C, 10 min), washed twice in assay buffer (Ringer’s solution, pH 
7.6)(17) by centrifugation (13,000x g, 4˚C, 3 min), and adjusted to an optical density of 0.1 at 
600nm in assay buffer. For kinetic studies with the wild-type M23, 3H-thymidine substrate as 
required, was added in a volume of 100 µl to a 2 ml microcentrifuge tube containing 900 µl 
of cell suspension, so that final concentrations of thymidine ranged from 0 to 500 nM. To 
determine an adequate reaction time, 50 µl samples were taken at various time points (0 to 30 
min) from the reaction tubes and vacuum-filtered through pre-wetted filter membranes (0.22 
µm-pore size). The membranes were immediately washed 6 times with 1 ml of washing 
buffer (100 µM unlabeled thymidine in assay buffer). After drying at 65˚C for 3 hr, the 
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radioactivity remaining on the filter was measured with a liquid scintillation counter. The 
thymidine uptake was determined in nM/mg of cell protein (Lowry Protein Assay, Pierce). 
Thymidine uptake in four transporter mutants and the corresponding complemented strains 
were similarly measured. For substrate competition assays, various unlabelled substrates and 
3H-thymidine were simultaneously added to the 900 µl of cell suspension, adjusting to either 
a 40 fold excess of substrates to thymidine at 10 nM. At designated time points, 50 µl 
samples were taken and processed as described above. All assays were performed in 
duplicate on three independent mycoplasma culture stocks. Apparent Km and Kmax values 
were determined by fitting the data to the Michaelis-Menten equation (Prism, GraphPad, 
CA). 
 
Energy inhibitors and uptake assay 
To test whether the ability of thymidine uptake is energy-dependent, sodium 
orthovanadate, valinomycin, and dicylohexylcarbodiimide (DCC) were added to mycoplasma 
cells in assay buffer at a final concentration of 1 mM, 10 µM, and 10 µM, respectively. The 
cells were pretreated with the chemicals at 37˚C for 15 min, then, subjected to thymidine 
uptake assay. 
 
Results 
3H-Thymidine is taken up by a high-affinity transporter 
3H-thymidine uptake in the M23 wild type strain occurred with Km of 0.96 ± 0.7 nM 
and Vmax of 244 ± 6.76 nM/mg protein (Figure 1A), within the range characteristic of a high-
affinity transporter system. The time course of uptake of 3H-thymidine into M. bovis in the 
presence of 10 nM 3H-thymidine is shown in Figure 1B. The uptake of 3H-thymidine was 
nearly linear up to 1 min, at which point an almost maximum level of 3H-thymidine uptake 
occurred. Therefore, uptake inhibition assays were performed at 30 sec of incubation time. In 
contrast to the wild type, all transporter mutants (MBOTn 3754, MBOTn 2627, MBOTn 
2927, and MBOTn 3178) had almost completely lost their ability to transport 3H-thymidine 
(Figure 4). We expected that the substrate binding protein mutant (MBOTn 3754) might 
partially lose its capability of 3H-thymidine uptake. However, 3H-thymidine uptake by the 
mutant was completely abolished, suggesting that the substrate binding protein is an integral 
 82 
 
component of the transporter. Thus, each of the four proteins is indispensable for the 
biological function of the thymidine transporter in M. bovis. 
 
Identification of M. bovis genes encoding a thymidine transporter 
Thymidine uptake in M. bovis was mediated by an ABC transporter encoding the 
uptBACD genes. This transporter possesses structural features characteristic of ABC 
transporters abundant in both eukaryotes and prokaryotes. The complete nucleotide sequence 
of the ABC transporter of M. bovis strain M23 is shown in Figure 2, whereas the schematic 
diagram of the genes encoding the thymidine transporter is shown in Figure 3. The uptB gene 
(substrate binding protein) is separated by 200 bp from a uptACD gene cluster (ATP-binding 
protein and permeases) and is transcribed in an opposite direction from the three genes. Gene 
uptA, uptC, and uptD are overlapping each other by 14 bp, and 1 bp, respectively, and are 
transcribed in the same direction. Tight organization of the uptACD genes strongly suggests 
that they are processed by transcriptional coupling, causing a polar effect on the genes. 
Interestingly, a small open reading frame (ORF) is present between the uptB and uptA genes. 
This ORF may be a regulator-related protein but this function has not been characterized. 
The product of the uptB gene, a 467 amino acid protein, exhibits an exporter signal peptide in 
the first 23 amino acid residues and is followed by a basic membrane lipoprotein (bmp) motif 
from amino acid residues 64 to 431. The uptA gene encodes a cytoplasmic protein of 533 
amino acids, sharing a highly conserved motif with other ATP-binding proteins of ABC 
transporter systems (1). These include a Walker A motif at residue 20, a Walker B at residue 
433, and a C-loop at residue 425. The uptC and uptD genes encode integral membrane 
proteins of 669 and 324 amino acids, respectively, which likely form the permease structure. 
Homology searches with the individual genes identified matching genes in several species of 
mycoplasma, indicating that they are most likely conserved genes possessing a common 
biological function among mycoplasma species. 
 
Substrate specificity 
To test the effect of various substrates on thymidine uptake, substrate uptake 
inhibition assays were performed (Figure 5). Since thymidine is composed of nucleobase 
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thymine and deoxyribose, both nucleobases and pentoses were first tested. They did not 
affect the uptake of thymidine in M. bovis. With (deoxy) nucleosides, 40-fold excess of 
unlabeled thymidine completely abolished the ability of 3H-thymidine uptake, and other 
nucleosides, except deoxycytidine, also significantly inhibited thymidine uptake. On the 
contrary, 3H-thymidine uptake was slightly increased in the presence of deoxycytidine and 
similar results were obtained by addition of cytidine. To test whether the inhibitory effect of 
thymidine analogs on the ability of 3H-thymidine uptake is different from that of unlabelled 
thymidine, bromodeoxyuridine or gemcitabine were tested in the substrate competition assay. 
Bromodeoxyuridine had a significant inhibitory effect on 3H-thymidine uptake whereas 
gemcitabine had no effect in the assay (Figure 5). This indicated that structural modifications 
on the ribose-moiety (gemcitabine data) may not be critical in substrate recognition by the 
substrate binding protein, so long as the nucleobase-ribose structure is presented.  
 
Complementation test 
Complemented strains were generated by introducing plasmid pRIC-ABC carrying 
the entire uptBACD region and the cat gene into each transporter mutant and by selection on 
Friis plates (with 25 µg/ml chloramphenicol). The recovery of thymidine uptake in 
complemented strains was determined by thymidine uptake assay (Figure 7). The thymidine 
uptake in complemented strains fully recovered to the level of the wild type M23, indicating 
that loss of thymidine uptake was indeed as a consequence of disruption of each gene 
composing the transporter. 
 
Thymidine uptake was energy dependent. 
  Thymidine uptake was not affected by DCC (Fig 7), a F0 F1-ATPase inhibitor, 
indicating that the thymidine transporter may not be linked to F0 F1-ATPase activity. 
However, the P-type ATPase inhibitor, sodium orthovanadate, inhibited about 50% of the 
thymidine uptake. Because P-type ATPases are in general linked to ion transporters, this 
observation should be further studied. Valinomycin, a K+ ionophore, greatly inhibited the 
level of thymidine uptake (Figure 8). This may be a result of direct bacteriostatic effect or 
disruption of membrane potential of mycoplasma cells. Thus, the diminished uptake of 
thymidine in chemical-treated cells may reflect a decreased energy-generating capacity.   
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Discussion 
In this study we characterize a substrate-binding ATP-dependent ABC transport 
system, UptBACD, required for nucleoside uptake in M. bovis. Indeed, Mollicutes must 
acquire nucleotide precursors and this function is absolutely essential for survival from 
exogenous sources due to lack of de novo synthetic pathways for such molecules (16). The 
need for a nucleotide transport systems has long been proposed (11, 20) and related genomic 
sequences reported in recently sequenced Mollicutes genomes (23). However, such transport 
systems have not been fully characterized in Mollicutes to date. Studies have reported that 
nucleotide precursors presented in medium were incorporated into several Mollicutes and 
eventually their nucleic acids (14, 18-20, 34, 39). In addition, uptake of nucleoside 
monophosphates into M. mycoides subsp. mycoides has been demonstrated by substrate 
uptake assay (21). In these reports, the existence of a transport system responsible for the 
uptake of nucleotide precursors was proposed but not confirmed. In preliminary genome 
studies performed in M. bovis with a subtract hybridization library, gene uptB was defined as 
a putative lipoprotein named p48 in M. bovis strain PG45 (33), whereas gene uptA was 
named p59 in M. bovis PG45 and identified as a putative sugar ABC transporter ATP-
binding protein. Partial sequences of uptA and uptB of M. bovis PG45 are available 
(GeneBank, DQ354911). The entire nucleotide sequence of the nucleoside uptake system of 
M. bovis M23 was determined in the present study. This is the first report of a fully 
characterized active ABC transport system that is responsible for nucleoside uptake in 
Mollicutes.  
The absolute requirement for a substrate binding protein in certain ABC transport 
systems has been demonstrated in a ribose transport system in enterobacteria (3, 22). 
Therefore, it was suggested that a substrate binding protein must make contact with the 
domains of permease proteins presented on the periplasmic membrane to form a tertiary 
conformational structure (2, 22). Substrate capture specificity was driven by the substrate 
binding protein, and the binding resulted in triggering of substrate uptake by the permease 
proteins (2). In substrate competition analyses to determine the substrate-specificity of 
UptBACD of M. bovis, nucleobases and pentoses did not affect thymidine uptake, indicating 
that these molecules may not play a significant role by themselves in the substrate binding 
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process. The rate of thymidine uptake was completely abolished in the presence of 40-fold 
excess of the homologous nucleoside thymidine, as is typical of substrate uptake by an ABC 
transport system. However, various nucleosides also significantly inhibited thymidine uptake, 
indicating that UptBACD may not have strict substrate-specificity. In contrast, thymidine 
uptake in E. coli was highly sensitive to excess of the homologous nucleoside but relatively 
insensitive to other nucleosides (15). In Lactobacillus lactis, nucleotides can be transported 
by two different transporters that possess affinity to specific nucleotides (13). Unlike these 
examples, it has been proposed that transport systems in Mollicutes may function with 
multiple substrates to compensate for their small genome capacities (36). Interestingly, the 
increased level of thymidine uptake in the presence of excess deoxycytidine may occur as a 
result of its activating effect on thymidine kinase, a key enzyme in deoxythymidine synthesis 
(8).  
All mutants defective in transporting thymidine were able to grow in modified Friis 
medium, containing highly rich nutrient sources, including nucleobases, nucleosides, 
nucleotides, oligonucleotides, RNA, and DNA. This indicated that the uptBACD genes are 
not essential for survival of M. bovis. Thus, there may be alternative routes that enable M. 
bovis to uptake other thymine-related nucleotide precursors that can be eventually converted 
into dTTP by a salvage pathway in the absence of thymidine. The nucleotide dTTP, essential 
for DNA synthesis, can be formed by two different routes. First, dTMP can be synthesized 
from dUMP via the action of thymidylate synthase and subsequently converted to dTDP and 
dTTP by both thymidylate kinase and dTDP kinase. Second, dTMP can be converted from 
thymidine by thymidine kinase. However, thymidylate synthase has not been identified in M. 
bovis or the genetically related M. agalactiae (25), suggesting that M. bovis must uptake 
exogenous nucleotide precursors to generate dTTP. In this case, the existence of a transporter 
capable of transporting such molecules is inevitable. Interestingly, in M. mycoides subsp. 
mycoides, the thymidine-related transporter has been experimentally substantiated (40). In 
that report, the selected mutant was unable to incorporate 3H-thymidine, whereas the wild 
type was able to rapidly uptake it but lost its ability in the presence of unlabelled thymidine. 
In addition, the mutant was able to utilize thymine for DNA synthesis but grew slowly 
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compared to the wild type. This indicates that a thymidine-transporter can be compensated by 
other potential routes for the uptake of thymine-related nucleotide precursors.  
Our thymidine transport studies revealed that M. bovis mutants disrupted in each 
component gene of UptBACD completely lost their thymidine uptake ability, indicating that 
all of the individual components of UptBACD are required for a functional transport system. 
In addition, the impaired thymidine uptake ability in these mutants was recovered by 
introducing intact uptBACD genes, confirming that UptBACD requires all four components.  
Recently, a new class of nucleoside transporter has been characterized in Streptococcus 
mutans (38). Unlike other nucleoside transporters, this transporter belongs to a carbohydrate 
uptake subfamily of active ABC transporters, but is involved in ribonucleotide transport. The 
gene organization of the RnsBACD of S. mutans is very similar to that observed by us in M. 
bovis. In addition, RnsBACD could not transport ribose or nucleobases, in concert with our 
observations on the UptBACD transporter of M. bovis. 
The biological activity of an uptBACD mutant of M. bovis could potentially be 
impaired as a consequence of disruption of an important transporter that is directly related to 
bacterial replication. A mutant defective in the pyrimidine salvage pathway of Toxoplasma 
gondii had attenuated pathogenicity under in vivo challenge (6). For Salmonella 
typhimurium, a mutant requiring nucleotides was unable to grow in vivo (4). These results 
indicated that disruption of a metabolic pathway of microorganisms critical for their survival 
could affect the in vivo survival of the microorganism. Thus, the UptBACD transport system 
is likely to be needed in M. bovis when it colonizes nucleoside-poor environments in the 
host.  
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Figure 1. Kinetics of thymidine uptake in 
type). Thymidine uptake ability was measured for 10 min at the substrate concentrations 
indicated. The insert graph presents the time course of thymidine uptake at 10 nM of 
substrate. Uptake values at each concentration were the means ± S.D. from three independent 
cultures. Values were corrected by subtracting the amount of radioactivity detected at zero 
time point and fitted to the Michaelis
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1        TATTAAAATT ATATAGTGTC CAAAATTGGG AATTTTTTAA TGTATAATAC AAATCATGGA 
61       AAATAGATTG ATAGAAAATC AAAAAAGTAG TCAAAATGAA TTCAACAGAT TCAATAGAGC 
121      CACATCAGTA GTAAGCAGAA AAAATGCTTT TCTAGGTGCT TCAGTTGGTT GATTTTCATA 
181      TTCTACATTT GTCGCATTTA TTAGCGCTAT TGTAATGCTT GTATTTTTTA GCCATGCACT 
241      AGTATTTATG AAGCAAAACA TCTTTTTAGC ACTAGGGCTT TCGTTCTTGT TAATAATATT 
301      TATTTTTGTT GAATTTATTG TAGGCCCAAG AATGAGCTTT TGGACGCAGC TTGTCATAAT 
361      AACATTAAGC ATGGTTCTGT TTGGAATTGT TGTACTATCA TTTGCAATTG TTGAATTATT 
421      AGAAACGTTT GCTAAAGGTG CACAAAATAT AAACTTACCT CTTGCTCAAA CTTTTGGTGT 
481      CATAATTGCC CCAATTGTTA TTATGGCTAT TATGGCAATA TTAGCCTACT TTGATTTGAT 
541      TAAAATTAAA ATAGCATATG CATTAACAAT ATTTATATTC ATAAGTTTTT TATTTATTTG 
601      AATAATAAGC TCTTTCATTT TTAGCTCATG ACTTTATTCA TTAATTCCTG CATTTGGCTT 
661      TGCTTTAATG GTTTGTTATA TGGCTATTGA TTGATGACTA ATTAGCAGAT ACAACAAAGC 
721      ATTTAATGCT ACAGTAAGTA ATGAAGCAAC TAAAAAAGAA TTTATGAAGT TAACAATATA 
781      TTTTGGCTTC AAATTAGCAT ACGACTACTT ATGAGCTTTA ATTTACTTAG TAAAACTTAT 
841      TAGATTAGCT AAAAACTAGA ACAAAAAACC AGGACACGAT TAAATGTCTT GGTTTTTAAT 
901      TTTAGTAGCC TATTTTTGTG TTTCTTTAGC CAATCAGTTA ATCATTTTCC CAAATTGGTC 
961      AGCAGGTTGG TCTGGTCATT TTGTACCTAA AGCTTTTTTA GCTTCTTCCA ATTGACCTGA 
1021     TAAAGTTTTT TGAATTTCCG CTTTTTTACT TTCGTAGTAT TTAGTAGCTT CTTCCAATGC 
1081     TTTATTAGCA ATCTCATCAT TCTTTGAGTC TAATAATCCT GAAGTTGCAA CACCTACATA 
1141     TTTGCTTGCT TCATTTTCAC CATAACCAAA TACTTTAGCC TCACCATTTT TTTTACCAAT 
1201     TTCAAAGCCT GGTTGAAGCG ATAGACTATT TTCACCTTGA GAGTATAAGT CAGCTAAAAC 
1261     GTTATAAACA GCTTGACCAA TTAATTTCAT AACTGATGTA AATATTCTAT GACCCTTTAA 
1321     TGCATTCTTT TGGTCAGCGT CAACACCAAT AATGAATTTG TTTTTATCGC CTAACTTCTT 
1381     AATTTCTTTA GCTGTGTCAG AAGATAATGA TCCTGCAACT GGATATGAAG CTGTGGCCTT 
1441     AATTACTGAG TTAATAGCAG CAACTGCAAC GGGTTCACCA GAAGTAAATG ATGTTTTTAA 
1501     TTCAATTGTG TTATTTAATG ATTTAGTCTT AGCTTCTGGG TGTTCTTTAT TTCAGTCAAT 
1561     AATACCTTGG AATGTACCAG CTATAAAGTC AGAAACTGCT GGTCAAGGAA TACCACCGAA 
1621     GGCACCTATT GTACGTTTTT CAGGATTATC CTTGTAAATT TTTGAGAAGT AGTCAGCAAG 
 
 Figure 2. Nucleoside sequence of ABC transporter involved in thymidine uptake 
in Mycoplasma bovis strain M23. Substrate binding protein gene (uptB): 910-2316 
(complementary), Hypothetical protein gene: 2443-2895 (complementary), ATP-binding 
domain gene (uptA): 3004-4608, intergral membrane permease gene (uptC): 4577-6589, 
integral membrane permease gene (uptD): 6589-7566. 
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1681     AGCACGACCA GCAATATATG CAGCTTGTTT AGTGTCAAAT ATTACAGGAA TTAAGCGTCC 
1741     TTGACCAATT TTGTCAACAA ATGCTTTTGC TGCAGGTTCG CCAGTGCTTG CATCTTGTTG 
1801     GATATCAAAG TCAACAGTAA TAAAGACAAT ATTATTATCT TTAATCTTTT TAATGTATTC 
1861     TGGTTCTAAA CCATAAAGCG CTGCTTTGTG AGTAAATCCA CAAAGAACAA TGTATCTAAA 
1921     ACTACTATCA ATAGCGTTTT TGTATGAAGA TGCTAATTCA CCCTTTTTAG GTTCGTAAAC 
1981     TTTATTTCTT AAGTTTTTAT TACCACTAAC TTGCGCCTTA TCTAATCCAA GTTCATATGA 
2041     AATTTTATGA ACTGCTTCTC AACCAGATTG ATTGAATGAT TCATCATGCA CAGATCCTTC 
2101     ATCAGTTATA AATGCTGCCC TTGGTGCATT ATCAACGGTT AAACCATCTC TTAGTTTTAA 
2161     TCCTTTACGA GACACGATGT GTGAAAGTGT TGTAACAGTT TTCACTCCAT CAACTTCAGT 
2221     TTCTTTAAAG TATTTATCAC CACATGAAGC AGCAACCAAT GGCACTGATA GAACAGGAGC 
2281     GGCTCCTAAA AATAGATAGA ATTTGTTTTT TTTCATATTG ATCCCTAATT CAAATATATT 
2341     AAGTTCTAAT GAATCAAAAT TTATCAAAAT TTCAATATAG TTTAGAACTA ACAATATTAT 
2401     ATTAAATTTA ATATTACTAA TAGCAGTGTG AAAAAGCCAA ATTTATTGCT GAAAAAACAA 
2461     AGTCGTTTCT ATCGTTTTTC TTTCATTTTG GGAAATTTTA GTTTTACCTT TATTTAAAAT 
2521     ATTAAAAACC AAAGCCCCTA TAAATAAGTT AAATTTGATT GACAAGTTTC CTTGACGGTG 
2581     CTCATTTCAC AATTTTTCTC CGTCTTTCTT TTTTAATAAG AAATTTGTTC ATTTGCTTAA 
2641     CTTTAAAAGT GACAAAAAAG GGTTAATTAT AAGAATTAAA GATAAAAAAC TCAATGATGC 
2701     TATTACGGTG AAAGCAATAA ATTGAGCTTT TTGTCTAAAG TAGACAATCG CTAACAATGT 
2761     CATAAAAAAC ATTAAGATAG ATACAAAACC TAAAAAAAGA ACTACTATTA ACTTAAATTT 
2821     TCTGTCCTCA TCATATGAAG CAATTTTTTC TAGTTTTTTA GCTTCAATAT TCATAATCAT 
2881     TATATTTTTA CTCATAAGCT ACCTTCAATG TTCTGAATTT CATATTCACA AGTTAATATA 
2941     GCCTAATTTA TATATAATTA AAGCATATTT ACTTAATATA TTTTATACAA GAAAGGGGGT 
3001     TTTATGGAAC ACAATTATGC CGTTGAATTT GAGCATGTGA CTAAGGATTT TGTTGGTATA 
3061     AGGGCTAATG ATGACGTGAC TTTTAAAGTT AAAAAAGGAA CAATTCATGC ACTTATTGGC 
3121     GAAAATGGAG CTGGGAAAAG TACTCTAACT TCAATTTTGT TTGGTTTGTA TGAACCAACT 
3181     GAAGGGTCTG TCAAAATTAA TGGTAAATCA GTTATTGTTA AAAACCCAAA TCAAGCTAAT 
3241     GAAATTGGAA TAGGTATGGT TCACCAACAC TTTAAATTGG TTGCTGCCTA TACTAATTTA 
3301     CAAAATGTGA TTATGGGTTC AGAGTTCACA TATCAACACT CTTTAGGAAC TTTAGATCTT 
3361     AAGTTAGCTA AAGCCAAGAT TAAAAGTATC CAAGAGCTTT ATGATTTACA CTTTAGTTTA 
3421     AACCAAAAAA CATCTAAAGC AACAGTTGCG ACTCAGCAAA AAGTTGAGAT TATGAAGATG 
3481     CTTTATCGCG ATGCTGAAAT CTTAATTTTT GACGAACCTA CTGCTGTTTT AACCGACCAA 
3541     GAAATCCAAG GTTTGCTAAA AACAATGCAA GTATTCAAGG AAAATGGCAA AACAATTATC 
3601     TTTATTTCCC ATAAACTCAA TGAAGTTAAA CAGGTAGCTG ACGAAGCAAC TGTTTTAAGA 
3661     AAAGGAAAGG TAATTGGAAC ATATGATGTA TCCAAAACCT CTATTCCACA GTTAGCTGAG 
 
 Figure 2. (continued) 
  
 94 
 
3721     GCTATGGTTG GACAAAAGGT TGTTGAAACA AAAAACACAG CATTTTTTGA AGGTTACGAT 
3781     AAATCTGAAT TTATTTCATT TAACAATGTT TCTACAAAGA AAAGCAGAGA CTCTGTTTCA 
3841     CTGAAAAACG TTTCGTTTAA AGTGCGCCCT GGAGAAATTT TAGCAATCGC TGGAGTTGAA 
3901     GGAAACGGAC AAGAAACACT AGAATATGTT TTAGCTGGAT TATTAAAACC TATTCATGGT 
3961     GAAATAAAAG TTAAAAACTT TGATTACGAT CCAAATAATC CAAAGTCTGT TCAAGAATTC 
4021     AACATTACAC ACTGGAGTGT TGATAAGAAA AACAGATTTG CAAAAATTAA TATTGTGCCA 
4081     GGCGACAGAC ACAAGCATGG ATTAGTTTTG GACTTTAGTA TTAGAGACAA TTCAATACTA 
4141     AGACTAATAA ATGATAAATA CTATGCCCCA CTTGGCTTCA TTAAAGCCAA TAAAAAAGAA 
4201     GAATTGTTCC AAAGTATTGT CACAAATTTT GATGTTAGAG GAACAAACCA CGGAAACTCT 
4261     TTAGCCAGAT CGCTTTCTGG TGGTAACCAA CAAAAAGCGA TTGTCGGTAG AGAAATGACC 
4321     ACAGAGCACA ATCTGCTTGT AATAGTTCAA CCAACCAGAG GGCTTGATGT CGGCGCTATT 
4381     GATTTAATTC ATAAAAAAAT TCTTTTAGAA AAACAAGCGG GTAAGGCTAT ATTGCTAATT 
4441     TCATATGAGT TAGATGAAAT TCTAGCATTA GCAGACACAA TTGCTGTTAT TAATGACGGA 
4501     AGAATTTTAG ATCTTAAACC TGCTTCACAG TTTAGTAGAA CTGAAATAGG TTTATTGATG 
4561     GCCGCATCAA ACAAAGATGA AGAATTGAAA GGAGAAGGCG ATGAATAGTA CTGCTGAAAA 
4621     AACAACAAAC CCTGTTCTTT CATTCTTCAA AAACTTCTGA AGCAAAGTCA AAAAAGGCGT 
4681     TAATGCCGAT AGCGCAGTAT CAACTAGAAG AAAAGCCTAT AACTCTATTT GATCGGTTGT 
4741     TTTTGGTATA TTCGTATCTA GCGTTGTGCT TTTACTATTT TTCCAAACCA ACCCTTTTGA 
4801     GTTTTTTACG CAAGTTGTTA AAGCAACAAC AAATAAAGGA AACATAGACT GAGTATATAT 
4861     ATTTATTATT TACTCATTAG CATCTATAGG TGTCGGATTC TCTTTTAAAA CAGGGCTATT 
4921     CAACATTGGG GTAGCTGGAC AAATGTCACT ATCAGGTGTT ATTTGTTTTG CGCTTATCAA 
4981     TAAAAGCAAT GTAATTGATG CTACTGGAGT TATAAAAAGC CAAGGCTTAG TATTTGCAAT 
5041     AATGCTTTTA TCTATTGTAA TAGGATTTTT ATATGCTGCA ATAGCAGGAT TATGTAAAGC 
5101     GTTTTTTAAT ATACACGAAG TTGTTTCTAC AATTTTGCTC AACTGAGTTG CTGTTTATAT 
5161     CGGAAGCTTT ATATTTGGAT CAAAATCGCC ATTTAATAAT GATTTTGTGT TCGCTAATAG 
5221     TCCAACCGGA TCAGCAACAA TAACTATAAC TGGTGGACTT TTTGATAAAG ATTCATTTTG 
5281     AATATTAGGA ATAGTTTTAG TTGCATTTGT TGCGCTAACA CTATATATGA TCTTTGCATT 
5341     TACATCATTG GGATACAAAA TCAAAATGAA TGGACTAAAC AAGGACGCTA GTTCATATGC 
5401     AGGCGTTAAT CAAAAGTTAA CAACAGTTTT ATCATTGGGC TTTTCTGGGG CACTCGCCGG 
5461     GCTAGCTGGT TTCATACATT TTGTTTATAA AGCCAAACAA TATGATGTTG TTGCTCTTTC 
5521     CAGTCCACTA CCACTAGGAT TTGACACTAT AGCCATATCT TTAATAGGAA TTAACTCCCC 
5581     AATAGGAATA CTTTTCTCAT CGGTTTTCTA CACAATGCTA GAGTTTTCTA GAATTGAGTT 
5641     AATTGGTTAT TACTCAACTA GTGGCGTTAA AGAGGGAGGA ATTGACTTAG TTGTTGGTGT 
5701     TATTATTTTC ACATCAGCAC TAGCTGTTAT GTTCACTAAT TTTAAACCTA TTCGCAAGTT 
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5761     TAGGATGTGG ATAGCATTGC TGACCCAAAA AGTATATAAA GGTCACTATG CAACATATAA 
5821     AGAAAAAGTA AAAACAGTTA AGGAAAATAC CAAAAAATTA CTTGATGAAG CGAAATTAGT 
5881     TTACCAAAAG AACAAACCAA AATACAATGA AATTAAATCT AAAATAAAGG CTCTTGAAAA 
5941     TGAAGTGTTA ATCAAGGTTA AACTGGGAAC TGATAAAAAA TCACAAACCA AACTTTCAAA 
6001     TCATGACATT GAAAAGATTT TCCAAGCACT AGCAAAACAA AAATCTGTTC TTAATCAAGA 
6061     GTTGGCTACA TATGGCTATT TTGATAAAAA AGATATTAAA AACCTTAAAA ATGTTAAGTT 
6121     AACACAACTT AAAGTTGAAC TTAACAAAAT TCAAGAAGAC TTATTAGATA ACTATCTACT 
6181     AATTGAATCA AGACTAATCT TTTTAAGAGA AACATATGAC CAAAAGCACT ATAAAATAGT 
6241     GAAAGAACAT AATTTAGATC AATTTAAAAA CGAGCTATTT TATCTTTATG AAGATAAAAA 
6301     ACAAATGATT AAAAATCATA AGTTAGAACT CAAAAAAGCA AAATCTGAAT CAAATAATGA 
6361     ATTAGTTGCA AAATTAACAT CTGAATTAAA CAAGCTAAAT GAAGAATTAG CAAAGATTAA 
6421     ATCGGATTAT GCAATTTATA GAAAAGACAT ATTAGCTTCA TACAAAGGAA TTGAAACAGT 
6481     CGACAATTCA AACAGCGAAA ATCCAATCAA GACAATAAAT CAAGATCTAT TTTTTGCATA 
6541     TAAAGAAAAA GTTAAACTAA TAGAAAGCTT CGCGACAGGA GGTGAATAAT GGAAAATATA 
6601     GCGTTTATAA CTAATGAAAC ATTATTTTTC GCTTGCGTCC TTGGCCTAGC TGCTATTGCT 
6661     GGAATATTTG CTGAAAGATC AGGAACTGTA AATATTGCAA TTGAAGGTAC TATGTCAATG 
6721     GGGGCCTTAG GATATTGCAT TATTTCAGCG CTTTTAACTA GTGGTGGAAG AATAACAGGA 
6781     GCAAATATTG ATGCACCGGG TATAGAGATT ATTTCATTAA TCTTTGCTGC TCTATTTGGT 
6841     TCATTATTCT CATTATTGCT AGGTTTATCA ACAATAAAAT TAAAAGCTGA GCACACAATA 
6901     ACAGGGGTTG CATTAAACCT TTTATCTGTA GGTATTTGTG CTGCTATTAT GAATCCTTCA 
6961     CTTTTAGGTA ATGCACAAAA GCAAATTGAT CACACTGTGC GTGAACTTGC ATTAAGCACA 
7021     AATTATAATG AATTTGGAAA CATTTTAAGT TTTAAACTAT TCCTTTTAAT ATCAGTTGTA 
7081     GTTATTTCAT GATTTGCTTT AAACAAAACA AAATGAGGGC TTCGTTTCAA AGCTGTTGGC 
7141     GAGAACCCAC AAGCTGTTGA CGTAGCCGGA ATAAATGTTT ATAAATACAA ATGAATGGGC 
7201     ATTGTTATTT CAGGTTGTAT AGCCGGAATG GCTGGTGGTG TGTTTGCTCA AAAACTACCA 
7261     TTTTCTGGAC AAACTAACGG ATTTGGTTTC CTTGCATTAG CTATTATGAT AATGTCTCAC 
7321     TGAAATGTAT TAATTGTTCC AGTTTGTGCC TTATTCTTTG GTTTCTTCCA ACAAATAGGT 
7381     GCATGACTAC TTGGCGTAGA ATTTGCTAAT ATTGTATCGA CTGAAACTAA TGATAGAGTT 
7441     CAAAAAATTG GAGAACTAAT TAAAGCAATT CCATATGTCT TAACGCTTAT CTCGATTATG 
7501     GCATTTAGTA AACTGTCTCC TGGCCCTGCA GCTTCAGGTA TAAACTATGA TAAGTCCAAG 
7561     AGATAAGTAA CAAAATATTA TCAGCCTAGC TTTTTGCTAG CTGATTTTAT TTATTGCTTT 
7621     TAAGCCTGTA AAACAGGCAA TAAGCCCACA TTCTGATAAC AAGACAACAT AGTTTTCTTT 
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Figure 3. Genetic map of the (
transporter of Mycoplasma bovis
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arrows indicate the transposon insertion sites on each gene and the name of the transposon 
mutants is indicated in boxes. 
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Figure 4. Inability of thymidine uptake in the transporter mutants of 
Mycoplasma bovis. 3H-thymidine uptake was measured at 10 nM thymidine and 37°C for 5 
min. The data represents mean ± S.D. from three independent cultures. M23: wild type, 
MBOTn 3754: substrate-binding protein mutant, MBOTn 2627: ATP-binding domain 
mutant, MBOTn 2927: transmembrane permease mutant, MBOTn 3178: transmembrane 
permease mutant. 
 
 
  
 98 
 
 
0 50 100 150 200
no substance
xylose
ribose
deoxyribose
arabinose
deoxyuridine
thymidine
deoxyguanosine
deoxycytidine
deoxyadenosine
uridine
cytidine
adenosine
uracil
thymine
cytosine
adenine
Thymidine uptake (%)
 
 
Figure 5. Inhibition of thymidine uptake by various substrates in Mycoplasma 
bovis. Uptake of 3H-thymidine was determined using 10 nM 3H-thymidine in the presence of 
40-fold excess of the indicated substrate at 37°C for 30 sec. Values are means ± S.D. from 
three independent mycoplasma cultures.  
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Figure 6. Effect of thymidine analogs on thymidine uptake in 
(A) chemical structure of thymidine analogs: (1)
(B) Inhibitory effects of thymidine analogs
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Figure 7. Recovery of thymidine uptake in transporter mutants by 
complementation of the impaired genes. The uptake rates were determined at 10 nM 
thymidine and 37°C for 1 min and shown as mean ± S.D. from three independent cultures. 
Complementation was accomplished using plasmid pRIC-3. 
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 Figure 8. Effect of energy inhibitors on thymidine uptake in Mycoplasma bovis. 
3H-thymidine uptake was measured with 10 nM 3H-thymidine at 37˚C for 5 min in the cells 
that were pre-treated with chemicals for 15 min at 37˚C.  Values are means ± S.D. from three 
independent cultures. DCC:dicylohexylcarbodiimide, SOV: sodium orthovanadate, VMC: 
valinomycin. 
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Table 1: Bacteria, mycoplasma strains, and plasmids. 
Bacterial strains 
and plasmids 
Descriptions 
Sources or 
references 
 
Mycoplasma  
  
M23 Field isolated parent strain (30) 
MBO 2627 Transposon mutant disrupted in ATP-binding domain gene This study 
MBO 2927 Transposon mutant disrupted in permease C protein  This study 
MBO 3178 Transposon mutant disrupted in permease D protein  This study 
MBO 3754 Transposon mutant disrupted in substrate-binding protein  This study 
C-MBO 2627 Complemented MBO 2627 carrying pRIC-ABC that contains 
the entire uptBACD gene region and chloramphenicol 
resistance gene 
This study 
C-MBO 2927 Complemented MBO 2927 carrying pRIC-ABC This study 
C-MBO 3178 Complemented MBO 3178 carrying pRIC-ABC This study 
C-MBO 3754 Complemented MBO 3754 carrying pRIC-ABC This study 
   
Plasmids  This study 
pRIT-1 pISM2062 carrying 4.9 kb HcII fragment containing 
tetracycline resistance gene (tetM) derived from pISM1002 
Lee and Rosenbusch 
(unpublished data) 
pRIC-1 pUC19 carrying tetM promoter region at SalI/BamHI This study 
pRIC-2 pUC19 carrying chloramphenicol acetyltranferase (cat) gene 
under control of tetM promoter 
This study 
pRIC-3 pISM2062 carrying the cat gene under control of tetM 
promoter at (EcoRV)SmaI 
This study 
pRIC-ABC pRIC-3 carrying the entire uptBACD gene region at 
SmaI/SmaI 
This study 
pISM1002 Source of tetracycline resistance (tetM) gene (13) 
pISM2062 Parent plasmid for constructs, carrying modified Tn4001  (10) 
pUC19 Parent strain for plasmid construction   
pBR328 Source of cat gene ATCC 
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Table 2. Primers used in this study.   
Name Nucleotide sequences (5’3’) Sources 
TpF TCAGTCGACGAATAACAAATATTGGTACATTATTACAGCT This study 
TpR TCAGGATCCCAATTGTTCCTCCATTCAAAAG This study 
CmF TCACAATTGATGGAGAAAAAAATCACTGGATATACCA This study 
CmR TCACCCGGGTTAAGGGCACCAATAAC This study 
catF GCATCAGATATCGAATAACAAATATTGGTACATTATTACAGC This study 
catR GCATCACCCGGGTTAAGGGCACCAATAACTGC This study 
ABC-F CTGCTACCCGGGAACTAGAACAAAAAACCAGGACACGAT This study 
ABC-R TCACTGCCCGGGTTCCGCTTATTCCTATTAACATAGACTTACTCC This study 
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CHAPTER 4.  IDENTIFICATION OF MYCOPLASMA BOVIS GENES REQUIRED 
FOR RESPIRATORY TRACT PERSISTENCE AND SYSTEMIC INFECTION IN 
CALVES USING SIGNATURE-TAGGED MUTAGENESIS 
 
Abstract 
 Invasive disease and chronicity are hallmarks of Mycoplasma bovis infections. This 
study was carried out to better understand the genetic basis of M. bovis disease and the genes 
required for establishment of systemic infection and lower respiratory tract persistence in 
calves. We analyzed 50 mutants selected from a Tn4001 random insertion library of the 
pathogenic M. bovis strain M23. A modified signature-tagged mutagenesis assay in calves 
was developed to screen the selected mutants. The mutants were grouped into 5 mutant pools 
consisting of 10 - 15 mutants per group, and 107 colony forming units of each mutant were 
inoculated intratracheally. At 7 days post-infection, tissue samples from the calves were 
analyzed by PCR assays specific for each mutant. We identified three mutants which could 
not be recovered from the tracheo-bronchial lymph node of infected calves. The defective 
genes identified in these non-invasive mutants were a polyamine transporter permease gene 
(potC), an uncharacterized ABC transporter permease gene, and oppF, an oligopeptide ABC 
transporter ATP-binding protein gene. These last two mutants were also unable to persist on 
the tracheal mucosa. In addition, a mutant defective in trigger factor (tig) was only recovered 
from the tracheo-bronchial lymph node of a few calves, and mutants with defective lipoate-
protein ligase (lpo) and peptide methyltransferase (hemk) exhibited limited persistence on 
tracheal mucosa. The signature-tagged mutagenesis assay in cattle allowed the identification 
of multiple genes associated with in vivo survival and virulence of M. bovis.  
 
Introduction 
 Mycoplasma bovis is a major etiological agent causing calf pneumonia, mastitis, 
arthritis, and other conditions (23, 27). After it was first isolated in 1961 in the USA (9), M. 
bovis infections have been shown to occur worldwide (23). The infections cause costly 
diseases leading to substantial economic losses to the cattle industry due to mortality, 
reduction of milk production in dairy cow, loss of weight gain and carcass value in beef (23, 
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27). Furthermore, once M. bovis infection enters a herd, it is very difficult to eliminate it 
from the affected herd. As with other mycoplasmas, chemotherapy generally provides limited 
clinical benefit and does not clear the infection. Since resistance to antimicrobials is well 
documented (14), there have been many efforts to develop vaccines against M. bovis 
infection, also with limited success (23-25). No virulence determinants have been identified 
in M. bovis, in part due to a lack of genetic tools useful for this mycoplasma. A recent report 
(5) indicated that M. bovis PG45 could be transformed with the Tn4001-containing plasmid 
pISM 2062 (16). We have constructed a random insertion library from the pathogenic M. 
bovis strain M23 using plasmid pRIT-1 (Lee and Rosenbusch, 2009, pers. comm.). In 
addition, signature-tagged mutagenesis (STM) screening has being widely used to determine 
putative virulence factors in many pathogens (3, 33). Recently, STM screening was 
successfully used to identify a virulence factor in Mycoplasma gallisepticum using a chicken 
respiratory infection model (12). Here, we report the establishment of a STM screening assay 
and its use to identify M. bovis genes required for establishment of systemic infection and 
tracheal mucosa persistence in cattle.  
  
Materials and Methods 
Mutant library and mutant pools 
 Strain M23 of M. bovis is a pathogenic strain isolated from a case of bovine 
pneumonia (30). A random mutant library of M. bovis strain M23 was constructed (Lee and 
Rosenbusch, pers. comm.). For STM screening in calves, we selected 50 candidate virulence 
gene mutants out of the 3,155 random mutants from the library, selecting only from among 
mutants having transposon insertions that were likely to functionally disrupt the gene under 
study (7). Mutants to be tested were those where the disrupted gene of interest was possibly 
associated with virulence, invasion, or in vivo survival of an organism, based on reported 
studies on animal mycoplasmas or gram-positive bacteria. Mutants were characterized 
according to gene function by sequence homology with genes from a preliminary genome 
annotation (Lee and Rosenbusch, pers. comm.). They could be classified into 14 functional 
categories as follows: translation (2), transcription (1), replication, recombination and repair 
(4), cell cycle control (1), membrane biogenesis (2), posttranslational modification, protein 
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turnover, and chaperones (5), energy production and conversion (2), carbohydrate transport 
and metabolism (8), amino acid transport and metabolism (6), nucleotide transport and 
metabolism (2), coenzyme transport and metabolism (2), inorganic ion transport and 
metabolism (4), other functions (7), and non-assigned (8). Thus, the mutants tested 
represented many categories of biological functions. The list of selected mutants is reported 
in Table 1. To prepare mutant pools, individual mutants were grown to mid-logarithmic 
phase in Friis broth supplemented with 20% fetal bovine serum (17). Aliquots were snap-
frozen on dry ice and stored at -70˚C. The viable bacterial concentration within each frozen 
stock was determined as colony forming units (CFU) per ml by titration on Friis agar plates. 
Mutant pools were prepared from frozen aliquots of each individual mutant resuspended in a 
total pool of 100 ml of phosphate-buffered saline (PBS), pH 7.4, supplemented with 1% 
horse serum, so that the pool contained the same concentration of each included mutant. 
 
Mutant screening in calves 
 Calves and calf inoculation: All animal experiments were conducted following 
protocols approved by the Institutional Animal Care and Use Committee. Six-month old 
Holstein calves confirmed mycoplasma-free by microbiological culture of nasal swabs and 
ELISA serology were purchased and housed in an animal isolation unit at Iowa State 
University. The calves were acclimatized for two weeks prior to initiation of the study. For 
mycoplasma inoculation, calves were sedated and a trochar was introduced into the trachea 
through a skin incision. A tracheal catheter was then inserted and advanced to the tracheal 
bifurcation. The mutant pool (100 ml) was slowly inoculated via the tracheal catheter. After 
inoculation, calves were observed daily and rectal temperature recorded.  
 Signature tagged mutagenesis screening in calves: To optimize STM in vivo assay 
conditions in calves, pools of 15 pseudo-mutants were prepared. Each pseudo-mutant had 
Tn4001 inserted at intergenic regions (between two functional genes). A frozen aliquot of 
each pseudo-mutant was pooled into a final volume of 100 ml PBS with 1 % horse serum, 
adjusting the viable mycoplasma number to 105, 107, or 108 CFU of each mutant, 
respectively. The pseudo-mutant pools were kept on ice and used to inoculate calves within 
30 minutes of preparation. To prepare an input DNA pool, 100 µl of each mutant was 
 107 
 
inoculated into 10 ml of Friis medium and incubated for 24hr. Genomic DNA was extracted 
from the mutant pool culture, and designated “input DNA”. Nasal swabs from both nares of 
each calf were taken daily. At necropsy, nasal swabs, uncoagulated blood, tonsils, tracheal 
swabs obtained from the lower third of the tracheal mucosa, and the tracheo-bronchial lymph 
node (TBLN) were taken. The TBLN was selected because of its prominent role in collecting 
lymph from most of the lung parenchyma in ruminants (2).  
 Screening by STM with candidate mutants was performed as described for pseudo-
mutants, with 10 - 15 individual mutants per pool, and 107 CFU of each mutant in the 
inoculum pool. Input DNA pools were prepared for each mutant pool as described above. 
The selected 50 mutants were assigned to 5 mutant pools that were used for STM screening 
using 2 calves per pool. Several candidate mutants were assigned to more than one pool, and 
were tested in more than one pair of calves.  
 The criteria used for defining whether recovery of a mutant was impaired from a 
given site were that the loss was observed to occur in all of the calves tested. Partial loss of 
recovery was assigned to results where more than half of the calves tested did not yield the 
mutant at the site. Recovery scores from nasal mucosa or tonsil were not considered reliable, 
since recovery of the wild type strain M23 was variable from these sites in calves inoculated 
at the tracheal bifurcation (Rosenbusch, pers. comm.) 
 
Mutant identification  
 Sample processing: Swab samples were collected into dry sterile tubes and kept on 
ice for processing. Paired nasal swabs were soaked in 2 ml sterile PBS on ice for 30 minutes, 
the swabs removed, and the PBS wash used to inoculate Friis broth. Eight tracheal mucosa 
swabs from each calf were soaked in 8 ml of sterile PBS and processed as above. Tissue 
samples (tonsil, TBLN) were weighed, 1 gm of tissue homogenized in 10 ml of sterile PBS 
using glass tissue grinders, and the suspension centrifuged (200x g for 3 minutes at room 
temperature) to retrieve the supernate. Each processed sample was inoculated 1:10 (v/v) in 
100 ml Friis broth supplemented with 67 µg/ml cefoperazone and 100 µg/ml bacitracin 
(Sigma, St. Louis, MO) as inhibitors of bacterial contamination. After 24 hr of incubation at 
37˚C, the broth cultures were filtered through membrane filters (0.85 µm in diameter) and 
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centrifuged (15,000x g at 4 ˚C for 20 minutes). The pellets were resuspended in 50 ml of 
fresh Friis broth with inhibitors and further incubated at 37˚C for 24 hr. Mycoplasma cells 
were harvested by centrifugation (15,000x g at 4 ˚C for 20 minutes). Total genomic DNA, 
designated “output DNA”, was extracted from pellets of enriched broth samples (Blood DNA 
Extraction Midi-Kit, Qiagen, Valencia, CA) and subjected to PCR analysis to identify 
individual mutants within the “output DNA”.  
 Mutant identification by PCR analysis: Presence of an individual mutant within 
“input DNA” or “output DNA” was determined by PCR using a mutant-specific primer 
which recognized sequence from the gene or a flanking gene, and a universal primer (U256) 
recognizing an outward sequence on IS256 L of Tn4001. Each mutant-specific PCR reaction 
resulted in a single PCR product of characteristic size, whether it was run on mutant DNA or 
pool DNA. Mutants that yielded amplicons that did not conform to this criterion were not 
used in these pools. The amplicon size for each mutant was in the range from 220 bp to 1100 
bp and the primers used are listed in Table 2.  
 
Results 
Optimization of STM assay 
 In a calf inoculated with a pseudo-mutant pool at 108 CFU per mutant, blood samples 
were culture-positive up to day 5 post-infection, confirming that M. bovis strain M23 was 
able to cause bacteremia following intratracheal inoculation. However, the calves inoculated 
with pseudo-mutant pools at 107 and 105 CFU per mutant showed intermittent culture-
positive blood samples, and these results were not used for analysis of mutants. All 15 
pseudo-mutants were recovered from tonsil, tracheal swab, and TBLN samples in the calves 
inoculated with pseudo-mutant pools of 108 CFU and 107 CFU per mutant while several 
pseudo-mutants were not recovered in these body locations from the calf receiving the 
pseudo-mutant pool at 105 CFU per mutant. The results were used to configure all STM 
screens, using pools of 15 mutants or less and 107 CFU per mutant. The selected 50 mutants 
were assigned to 5 pool groups where each group contained 10 - 15 mutants with 107 CFU 
per mutant.  
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Mutant recovery patterns 
Three distinct patterns of recovery were observed with the mutants. Mutants that behaved 
like the wild type (pattern A) were recovered from all calves in all samples, and principally 
from tracheal mucosa, and TBLN. Most mutants (42 out of 50) were categorized in this 
pattern. The second pattern (pattern B) included mutant MBOTn 627 that was recovered 
from tracheal mucosa but not from the TBLN sample. The functional defect did not impair 
mucosal colonization but did impair translocation to other tissues. The third pattern (pattern 
C) included mutants which were not recovered from either tracheal mucosa or TBLN, 
represented by mutants MBOTn 1283 and MBOTn 1290. The mutants were unable to 
colonize on the tracheal mucosa and thus were not available for translocation to the TBLN. 
Some mutants were observed to have only partially lost potential for tracheal mucosa 
colonization or translocation to the TBLN. Mutant isolation from blood or nasal swab 
samples was infrequent during the 7 days after inoculation, and occurred only with strains 
with recovery pattern A (data not shown). A summary of recovery results is presented in 
Table 3. Translocation to the TBLN and tracheal mucosa colonization were reliable 
indicators of M. bovis pathogenicity, and required separate colonization factors. Tissue and 
swab samples yielded representative amounts of genomic DNA of each recoverable mutant 
when processed by PCR (Figure 1). 
 
Identification of disrupted genes and their schematic features  
 Disruption of 3 genes resulted in recovery patterns distinct from the wild type.  
The spermidine/putrescine ABC transporter permease gene (potC) disruption in MBOTn 627 
was associated with translocation to the TBLN. An uncharacterized ABC transporter 
permease protein gene disrupted in MBOTn 1283, and an oligopeptide ABC transporter 
ATP-binding protein gene (oppF) disrupted in MBOTn 1290 were important in tracheal 
mucosa colonization. In M. bovis, potC belongs to a spermidine/putrescine ABC transporter 
that consists of an ATP-binding domain (potA), two permeases (potB and potC), and a 
substrate binding domain (potD). The genes overlap by 14, 5, and 11 nucleotides respectively 
in potABCD (Figure 1C), indicating that the genes are likely under control of a single 
promoter. Insertion of the transposon into potC is likely to also affect the potD gene function 
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due to polarity of the gene cluster, and consequently impair the biological function of the 
polyamine transporter. In mutant MBOTn 1283, the identified gene is part of a gene cluster 
identified as a characteristic ABC transporter (Figure 1A). The gene cluster consists of 
conserved predicted lipoproteins, an ATP-binding domain, and two integral transmembrane 
proteins. In particular, the last three genes overlap by 16 and 59 nucleotides respectively, 
indicating that the genes are likely to be under the control of a single promoter. The 
transposon was inserted into the first integral transmembrane gene, suggesting that one or 
both transmembrane genes are inactivated due to the polarity of the gene cluster. The 
biological function of this ABC transporter has not been characterized. In mutant MBOTn 
1290, the oppF gene was interrupted by transposon insertion, and this gene is part of an 
oligopeptide ABC transporter that includes a hypothetical protein (a putative substrate 
binding domain oppA), two permease proteins (oppB and oppC), and two ATP-binding 
domains (oppD and oppF). Disruption of the oppF gene results in inactivation of one ATP-
binding domain and the loss of energy abolishes the functionality of the transporter. 
While not eliminating recovery from the TBLN, a mutant (MBOTn 230) defective in 
the tig trigger factor gene was only recovered from this site in 1 out of 4 calves tested. 
Similarly, a mutant (MBOTn 1240) defective in the lpo gene for lipoate protein ligase, and a 
mutant (MBOTn 363) defective in the hemk gene for peptide methyltransferase were both 
recovered from the tracheal mucosa of only 2 out of 6 calves tested.  
 
Discussion 
 Although M. bovis causes a variety of diseases in beef and dairy cattle, the molecular 
pathogenesis of these diseases is unknown. It has been reported that M. bovis is able to infect 
internal organs and tissues, such as liver, kidney, lung, joints, and mammary glands as a 
consequence of either invasion across airway and alveolar epithelium or lymphatic drainage 
from alveoli (1, 15, 32, 37). To establish systemic infection, M. bovis may need to survive 
and replicate in the infected host in various environments and have the ability to confront 
scarcity of nutrients and components of the host’s immune defenses.  
 Microbial pathogens have multiple biological properties that enable them to attach, 
colonize, invade at specific entry sites, and replicate in the environment of the infected host 
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(11). Thus it is highly desirable to use in vivo assays in the natural host to determine the 
genes responsible for such complicated infection processes (18). In particular, STM has often 
been used to identify mutants unable to survive specific conditions in the infected host, and 
has led to the identification of  genes critical for establishment of bacterial diseases (3, 21, 
22, 33). Since STM relies on the ability of the pathogen to survive and replicate as a mixed 
population in the infected host, several parameters must be optimized to obtain reproducible 
outcomes in a particular host. The parameters include the complexity of mutant pool, 
inoculum dose, administration route, duration of infection, and choice of animal host. The 
parameters must be optimized empirically because they are obviously interrelated to each 
other (18, 26).  
 The ability of microorganisms to survive in vivo is a result of complex interplay 
between the host environment and the microorganism (18). A constant supply of a nutrient 
utilized by a gene that is required for in vivo survival may be a critical factor in the ability of 
a pathogen to establish disease. Many nutrients are obtained from exogenous sources by 
mycoplasmas due to their limited synthesis pathways. Thus, the ability to incorporate 
molecules through membrane-associated transport systems appears to be a critical factor for 
in vivo survival of M. bovis. In our study, two transporters (oligopeptide transporter 
oppABCDF and an uncharacterized transporter) were required for colonization on the 
tracheal mucosa. In Mycoplasma mycoides subsp. mycoides, a glycerol transporter (gtsABC) 
has been defined as a virulence factor associated with hydrogen peroxide production and 
induction of cytotoxicity (10, 28, 38, 39). The mRNA expression of oppD (ATP binding 
protein of oligopeptide transporter) of Mycoplasma hyopneumoniae was slightly up-regulated 
during in vivo infection (20) and under iron-depletion conditions (19). An oppA mutant of 
Streptococcus Group A was reported to be attenuated in mortality and tissue damage in a 
mouse model (40). The oligopeptide ABC transporter was required for growth and survival 
of Streptococcus agalactiae in a rat model, and was correlated to lack of amino acid 
biosynthetic capabilities in this organism (13, 34). 
We show here that another transporter (potABCD) is required for translocation of M. 
bovis to the TBLN. The mRNA transcription of potA was up-regulated in M. hyopneumoniae 
during in vivo infection (20), and mRNA of potB was up-regulated under iron-limiting 
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growth of the mycoplasma (19). In Streptococcus pneumoniae, both potA and potD genes 
were identified as virulence-associated genes by STM in a mouse model (29, 35, 41). The 
polyamines transported by Pot transporters (spermidine and putrescine) have multi-factorial 
biological functions in living organisms, including stress responses which may be more 
important than their metabolic role (31, 36). 
The tig gene defect resulted in partial loss of translocation of the mutant to the TBLN. 
The gene product is a ribosome-associated chaperone that has been shown to be involved in 
persistence of Listeria monocytogenes in lymphoid tissues and in stress tolerance (4). 
Disruption of the peptide methyltransferase HemK resulted in partial loss of tracheal mucosa 
colonization of mutant M. bovis. A similar gene disruption was shown to eliminate protection 
against phagocytosis in Yersinia pseudotuberculosis (8), and prevent systemic infection in 
Streptococcus pneumoniae (6), although in both reports the effect was ascribed to polar effect 
on a nearby gene. Peptide methyltransferase plays a critical role in translation termination by 
methylation of terminator peptides. A lipoate protein ligase (lpo) disruption mutant of 
Mycoplasma gallisepticum was shown to have lost tracheal mucosa colonization ability and 
resulted in lowered tracheal lesion scores in chickens (12). Similarly, the lpo gene may be 
involved in tracheal mucosa colonization in M. bovis.   
 In summary, this study demonstrated that our STM technique is applicable to identify 
M. bovis genes required for survival of the mycoplasma in its natural host. Up to 2 genes 
were shown to be required for translocation to a regional lymph node, and up to 4 genes were 
shown as required for tracheal mucosa colonization. 
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 Table 1. Tn 4001 mutants of Mycoplasma bovis tested in cattle. 
Mutant Hypothesized function 
M. agalactiae 
homolog 
CDS length 
(nucleotides) 
Transposon 
insertion site 
(nucleotides) 
MBOTn 99 Hypothetical protein  MAG 6950 654 59 
MBOTn 113 Foramidopyrimidine DNA MAG 3150 837 396 
MBOTn 126 Hypothetical protein  MAG 5870 896 555 
MBOTn 136 Trigger factor MAG6310 864 790 
MBOTn 151 RecA MAG 5500 990 762 
MBOTn 169 UvrABC system protein A MAG 3790 2829 780 
MBOTn 191 
Peptide methionine sulfoxide 
reductase MAG 3130 927 613 
MBOTn 216 Variable surface protein O - 756 92 
MBOTn 230 Trigger factor Tig MAG 1540 1503 591 
MBOTn 245 Conserved hypothetical protein - 1725 77 
MBOTn 255 
Large-conductance mechanosensitive 
channel MAG 5570 420 45 
MBOTn 286 HIT-like protein (cell cycle regulation) MAG 1990 384 64 
MBOTn 293 Aminopeptidase MAG 5520 1359 841 
MBOTn 307 
Oliogopeptide ABC transporter,  
substrate-binding protein(OppA) MAG 0380 2952 794 
MBOTn 359 Cell division protein FtsZ MAG 3710 1139 11 
MBOTn 362 
NADH dependent flavin 
exidoreductase MAG 4830 1182 500 
MBOTn 363 Peptide methyltransferase (Hemk) MAG 7340 720 36 
MBOTn 395 ClpB MAG 6240 2166 86 
MBOTn 420 Chaperone protein DnaK MAG 7280 1815 133 
MBOTn 461 Endopetidase O MAG 3680 1944 1018 
MBOTn 516 NADH oxidase  MAG 2460 1347 167 
MBOTn 525 Thymidine phosphorylase MAG 5120 1293 132 
MBOTn 526 Phosphate acetytransferase  MAG 1390 972 465 
MBOTn 568 
Hypothetical protein, predicted 
lipoprotein  - 1263 951 
MBOTn 585 tRNA/rRNA methyltransferase MAG 0410 699 147 
MBOTn 592 ABC transporter, permease protein MAG4600 1860 494 
MBOTn 593 DNA-damage repair protein MucB MAG 0740 1245 10 
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 Table 1.(continued) 
Mutant Hypothesized function 
M. agalactiae 
homolog 
CDS length 
(nucleotides) 
Transposon 
insertion site 
(nucleotides) 
MBOTn 627 
Spermidine/putrescine ABC 
transporter permease PotC MAG 1270 891 6 
MBOTn 671 Sugar ABC transporter permease MAG 0150 2010 582 
MBOTn 691 Hemolysin-related protein MAG 2390 1290  
MBOTn 719 Hypothetical protein  MAG 0880 387 84 
MBOTn 740 Mg2+ transporter protein (Mgte) MAG 3070 1458 833 
MBOTn 817 
Oligopeptide ABC transporter, 
permease protein (OppB) MAG 1010 1119 689 
MBOTn 827 Chromate transport protein MAG 6760 666 324 
MBOTn 863 
ABC transporter, ATP-binding protein 
P59 MAG 0140 1602 22 
MBOTn 916 
Oligopetide ABC transporter, 
permease protein (OppB) MAG 0370 1083 713 
MBOTn 930 Pyruvate kinase MAG 1440 1434 162 
MBOTn 962 Hypothetical protein MAG 0330 429 37 
MBOTn 990 
Pseudogene of glycerol transporter 
subunit A MAG 6560 1221 574 
MBOTn 1008 Proline iminopeptidase (Pip) MAG 0710 900 447 
MBOTn 1014 Hypothetical protein  MAG 0420 582 134 
MBOTn 1126 Hypothetical protein MAG 2500 2085  1242 
MBOTn 1156 Glycerol facilitator factor MAG 4480 789 250 
MBOTn 1159 
Glycerol ABC transporter, ATP-
binding component MAG 2310 1216 1170 
MBOTn 1221 Hypothetical protein  MAG3650 726 620 
MBOTn 1240 Lipoate-protein ligase LpoA  MAG 0070 972 563 
MBOTn 1273 Thiamine biosynthesis protein Thil MAG 1310 1134 517 
MBOTn 1283 ABC transporter, permease protein  MAG 5060 1065 391 
MBOTn 1290 
Oliogopetidase ABC transporter, ATP-
binding protein (OppF) MAG 1040 2400 549 
MBOTn 2452 P48, predicted protein  MAG 0120 1404  
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 Table 2. Oligonucleotides used in this study to identify mutants. 
Mutant name Name of primer Nucleotide sequence (5’3’) 
 U 256 (universal) CGAGGGATTCCGAGGACTG  
MBOTn 99 Tp 99 CCAAGGTCCCCAGGTCT 
MBOTn 113 Tp 113 AGGCAAATTTGCTCGCATGTGA 
MBOTn 126 Tp 126 GCAAGCCTGCTATGTGCGTTAATAC 
MBOTn 136 Tp 136 TGCTTTGGAACAACTCATGCAGAC 
MBOTn 151 Tp 151 GCCTTCATAAGCATATCAAGCG 
MBOTn 169 Tp 169 CCTCCACTAAGAGTTTCGGCATTC 
MBOTn 191 Tp 191 CTATGACATTTCAGCTGATGGTGCATC 
MBOTn 216 Tp 216 GCATCTGTATCTTCGTCGACTTCGTC 
MBOTn 230 Tp 230 GATAATATGTAAAGTTCTGTGCGCGGAAAC 
MBOTn 245 Tp 245 CGATTATGTTCTCCCGTTGGGATAG 
MBOTn 255 Tp 255 GCAACCACTGCAACTGGAG 
MBOTn 286 Tp 286 CATATATAAATCAAATTGTGCCAGTAGGCA 
MBOTn 293 Tp 293 TGTGTTAGAATACAATGGAAACCCTGATTC 
MBOTn 307 Tp 307 CACAACATTTGATAGTGATGAAGGTTCACTAGC 
MBOTn 359 Tp 359 CATTCTTTTCCAACCTTAGGATCACCA 
MBOTn 362 Tp 362 TAGGTGAGGATGATGGCGTTG 
MBOTn 363 Tp 363 TGTTCTACCGTTGAACTACACTCCTAC 
MBOTn 395 Tp 395 GATCCGAAATCTATTGGATGAGGTCAG 
MBOTn 420 Tp 420 AGCCGCTAAAAGCGGAAGGAA 
MBOTn 461 Tp 461 ACTCGTCATTAGTTGAGTTTTCTCCTAGTG 
MBOTn 516 Tp 516 CGGCATCTTCTAAACGGGTTAGAG 
MBOTn 525 Tp 525 CCTGCCGATTGGTCTAGACAT 
MBOTn 526 Tp 526 CGTTCGCATATACCAGTGCCTAG 
MBOTn 568 Tp 568 ACTGTTATCCTACTGGTGAGTGATCA 
MBOTn 585 Tp 585 CAGTTGAAGTTACATCAGTCGATCTGTC 
MBOTn 592 Tp 592 TGATATGGTCTGTTAATAAAGTGAGCAGCA 
MBOTn 593 Tp 593 GACTTAATTAACTGTCTAGGTCACTAG 
MBOTn 627 Tp 627 TCTCATGACTTAGGTAACGGACCA 
MBOTn 671 Tp 671 GGTAGAGAAATGACCACAGAGCAC 
MBOTn 691 Tp 691 GCATATACTAGTCTAAGTCCAGGCAGGA 
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 Table 2. (continued) 
Mutant name Name of primer Nucleotide sequence (5’3’) 
MBOTn 719 Tp 719 GACAAAATCAATAGTGGCGGCTCAAC 
MBOTn 740 Tp 740 GATATAAATAGTGCTACTGATGTGCCA 
MBOTn 817 Tp 817 CATCTCTTTCTAGACCATATACAGGAACAGAC 
MBOTn 827 Tp 827 TACAATCAGTAATGCTACACCTGGTGT 
MBOTn 863 Tp 863 CAGCAACCAATGGCACTGATAG 
MBOTn 916 Tp 916 TCACTCTTTGTAAGCAAGCGGTCA 
MBOTn 930 Tp 930 GCTCTAGTAGGATGCGGA 
MBOTn 962 Tp 962 CAATTCAGTTGCCGGCAC 
MBOTn 990 Tp 990 GAAGTATATAAACAGTACATTGCGAGCGGA 
MBOTn 1008 Tp 1008 GACCAGGTGCTGGTTGCA 
MBOTn 1014 Tp 1014 CTGTGCATAAGTATTAAATGCCTCTG 
MBOTn 1126 Tp 1126 TAAATATCCTTAATAAAATTCGTCTAGCAG 
MBOTn 1156 Tp 1156 ATGGCTGGCTTAGCTACTGGATAC 
MBOTn 1159 Tp 1159 GCAAGATGCTTTAAAGCTTAGCGATTC 
MBOTn 1221 Tp 1221 TGGCTCATCACATCTTCAGCATC 
MBOTn 1240 Tp 1240 GAAGATCCATCAATCACTGGCGATG 
MBOTn 1273 Tp 1273 GGTATCACTAGTTATAGCCCGGTT 
MBOTn 1283 Tp 1283 TGACTTTGTAACTCCTCAGCCTGT 
MBOTn 1290 Tp 1290 CTAAACTGCGCTTCTTTTCG 
MBOTn 2452 Tp 2452 CCACTAACTTGCGCCTTATC 
 
  
 121 
 
 Table 3. Mutant recovery data from STM assays in calf model. Mutants are 
grouped by functional category. 
Mutants and 
Functional category 
Putative function of ORF 
Number of positive calves 
/total number of calves 
Tonsil Trachea TBLN 
 
Translation  
    
MBOTn 113 Foramidopyrimidine DNA 2/2 2/2 2/2 
MBOTn 363 Peptide methyltransferase (Hemk) 5/6 2/6 2/6 
MBOTn 585 tRNA/rRNA methyltransferase 2/2 2/2 2/2 
 
Replication, recombination, and repair 
MBOTn 151 Recombinase A protein 1/2 2/2 2/2 
MBOTn 169 Excinuclease ABC subunit A 2/2 2/2 2/2 
MBOTn 593 DNA-damage repair protein MucB 2/2 2/2 2/2 
 
Posttranslational modification and protein turnover 
MBOTn 191 Peptide methionine sulfoxide reductase 2/2 2/2 2/2 
MBOTn 230 Trigger factor 2/4 4/4 1/4 
MBOTn 395 ATP-dependent Clp protease subunit B  1/2 2/2 2/2 
MBOTn 420 Chaperone protein dnaK 1/2 2/2 2/2 
MBOTn 461 Endopetidase O 1/2 2/2 2/2 
MBOTn 293 Aminopeptidase 5/6 6/6 6/6 
 
Membrane biogenesis 
MBOTn 255 Large-conductance mechanosensitive channel 2/2 2/2 2/2 
 
Carbohydrate transport and metabolism 
MBOTn 990 Glycerol transporter subunit A (pseudogene) 2/2 2/2 2/2 
MBOTn 1156 Glycerol facilitator factor 1/2 2/2 2/2 
MBOTn 1159 
Glycerol ABC transporter, ATP-binding 
component 
2/2 2/2 2/2 
 
General function  
    
MBOTn 286 HIT-like protein (cell cycle regulation) 2/2 2/2 2/2 
MBOTn 516 NADH oxidase  1/2 2/2 2/2 
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 Table 3. (continued) 
Mutants and 
Functional category 
Putative function of ORF 
Number of positive calves 
/total number of calves 
Tonsil Trachea TBLN 
MBOTn 691 Hemolysin-related protein 2/2 2/2 2/2 
MBOTn 930 Pyruvate kinase 0/2 2/2 2/2 
MBOTn 1008 Proline iminopeptidase (Pip) 2/2 2/2 2/2 
 
Energy production and conversion  
MBOTn 362 NADH dependent flavin exidoreductase 2/2 2/2 2/2 
MBOTn 526 Phosphate acetyltransferase  2/2 2/2 2/2 
 
Cell cycle control, mitosis 
MBOTn 359 Cell division protein FtsZ 2/2 2/2 2/2 
 
Coenzyme transport and metabolism  
MBOTn 1240 Lipoate-protein ligase LpoA 2/6 2/6 3/6 
MBOTn 1273 Thiamine biosynthesis protein Thil 2/2 2/2 2/2 
 
Transcription  
MBOTn 136 Transcription regulator 2/2 2/2 2/2 
 
Cell surface structure and membrane proteins 
MBOTn 216 Variable surface protein O 2/2 2/2 2/2 
MBOTn 2452 P48, predicted protein 1/2 2/2 2/2 
 
Inorganic ion transport and metabolism 
MBOTn 740 Magnesium (Mg2+) transporter protein  2/2 2/2 2/2 
MBOTn 827 Chromate transport protein 2/2 2/2 2/2 
 
Substrate binding proteins/Transporters 
MBOTn 307 
Oliogopeptide ABC transporter, substrate-binding 
protein (oppA) 1/2 2/2 2/2 
MBOTn 592 ABC transporter, permease protein 3/6 6/6 4/6 
MBOTn 627 
Spermidine/putrescine ABC transporter permease 
potC 
1/4 2/4 0/4 
MBOTn 671 Putative sugar ABC transporter permease protein 1/2 2/2 2/2 
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 Table 3. (continued) 
Mutants and 
Functional category 
Putative function of ORF 
Number of positive calves 
/total number of calves 
Tonsil Trachea TBLN 
MBOTn 817 
Oligopeptide ABC transporter, permease protein 
(oppB) 4/8 6/8 4/8 
MBOTn 863 ABC transporter, ATP-binding protein P59 1/2 2/2 2/2 
MBOTn 916 
Oligopetide ABC transporter, permease protein 
(oppB) 2/2 2/2 2/2 
MBOTn 1283 ABC transporter, permease protein 0/2 0/2 0/2 
MBOTn 1290 
Oliogopetide transporter, ATP-binding protein 
(oppF) 0/2 0/2 0/2 
 
Nucleotide transport and metabolism 
MBOTn 525 Thymidine phosphorylase 2/4 3/4 3/4 
 
Genes of unknown function 
MBOTn 99 Hypothetical protein 1/2 1/2 1/2 
MBOTn 126 Hypothetical protein  2/2 2/2 2/2 
MBOTn 245 Conserved hypothetical protein (lipoprotein) 2/2 2/2 2/2 
MBOTn 568 Hypothetical protein, predicted lipoprotein 2/2 2/2 2/2 
MBOTn 719 Hypothetical protein  2/2 2/2 2/2 
MBOTn 962 Hypothetical protein  2/2 2/2 2/2 
MBOTn 1014 Hypothetical protein  0/2 2/2 2/2 
MBOTn 1126 Hypothetical protein  0/2 2/2 2/2 
MBOTn 1221 Hypothetical protein  2/2 2/2 2/2 
 
 
  
  
 Figure 1. PCR analysis of signature
PCR amplicons of input DNA for mutant pool 1. (B) Output PCR profile obtained from the 
tracheo-brochial lymph node sample collected from a calf inoculated with mutant pool 1. M: 
DNA molecular weight marker, Lanes 1 
and 9 (ABC transporter ATP
from the TBLN sample of the calf. 
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-tagged mutagenesis screening
– 9: individual mutant amplicons. Lanes 5 (
-binding domain) identified mutants that could not be recovered 
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 Figure 2. Schematic features of three transporters. (A) uncharacterized ABC 
transporter, (B) polyamine transporter, (C) oligopeptide transporter.  The arrows indicate the 
direction of individual genes belonging to transporters. Transposon insertion sites are 
indicated by a black arrowhead. The shaded arrows represented the genes disrupted by the 
insertion of the transposon. Gene names are shown on the genes and the sizes of genes are 
indicated in parenthesis under the gene.  PM: ABC transporter permease, ATP: ABC 
transporter ATP-binding domain protein, HP: hypothetical protein, potA: polyamine 
transporter A, potB: polyamine transporter B, potC: polyamine transporter C, potD; 
polyamine transporter D, oppB: oligopeptide transporter B, oppC: oligopeptide transporter C, 
oppD: oligopeptide transporter D, and oppF: oligopetide transporter F. 
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CHAPTER 5.  GENERAL CONCLUSIONS AND SUMMARY 
 
 Mycoplasma bovis is a significant bacterial pathogen that causes a variety of diseases 
in cattle. Even so, studies on this pathogen have been limited and focused on diagnostics and 
treatment of the diseases. The unavailability of molecular tools to genetically manipulate this 
pathogen has limited the opportunity to investigate this pathogen at the genetic level, such as 
by comparing isogenic mutants, or determining its virulence genes.  
 In this study, we arbitrarily annotated the genome of M. bovis strain PG45. Then, we 
developed genetic tools useful for this pathogen and used them to establish a global random 
mutant library. The mutant library was used to determine which genes are essential or 
dispensable in M. bovis, with comparison to data on global mutagenesis of other mycoplasma 
species. These studies provided valuable information about the genome and the physiology 
of M. bovis. From the mutant library, we defined an ABC transport system responsible for 
the uptake of nucleosides as nucleotide precursors. This finding is the first report that 
mycoplasmas are able to uptake exogenous nucleotide precursors via an active and 
genetically defined ABC transporter. We deduce that this transporter must be a part of 
important biological functions of M. bovis, particularly during colonization of its specific 
host, the bovine.  
 Considering the pathogenicity of this mycoplasma, we established a modified 
signature-tagged mutagenesis (STM) in vivo persistence assay and applied it to define genes 
responsible for either establishment of systemic infection or colonization on the respiratory 
tract of the host. To our knowledge, this is the first application of STM to a large animal 
species. We identified three genes disrupted in non-invasive mutants, a putrescine/spermidine 
ABC transporter permease gene (potC), an uncharacterized ABC transporter permease gene, 
and an oligopeptide ABC transporter ATP-binding domain (oppF). The last two mutants 
were also unable to persist on the tracheal mucosa of cattle, an additional phenotype that 
could be studied with our STM assay. Taken together, our studies greatly expanded the 
understanding of the basic physiology and pathogenicity of M. bovis.  
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Recommendations for future research 
 As an extension of our research, we visualize two different approaches for further 
studies to better understand M. bovis at the genetic level. The first direction would be to 
focus on the basic physiology of this pathogen. The discovery of the thymidine transporter 
confirms the existence of an entry route of some exogenous nucleotide precursors. However, 
the genes encoding the nucleoside transporter turned out to be non-essential genes, allowing 
the mutants to grow in the highly enriched modified Friis medium where other forms of 
nucleotide precursors exist. The ability of transporter mutants to grow in modified Friis 
medium strongly suggests that there are other active transport systems able to uptake other 
forms of nucleotide precursors. Further studies to define other transporters that participate in 
the uptake of other forms of nucleotide precursors would provide an opportunity to complete 
a study of entry routes for nucleotide precursors, and eventually define the salvage pathways 
for nucleotide synthesis in mycoplasma. 
 No defined virulence factors have been identified in M. bovis even though severe 
disease and mortality can be produced by it in cattle of all ages. In general, clinical signs of 
most mycoplasma infections are considered to appear as a consequence of multifactorial 
processes and interactions between the mycoplasma and the host environment, except for 
some mycoplasmas where active virulence factors have been defined. In the case of M. bovis, 
colonization at an entry site, invasion into deep tissues, and systemic infection must be 
crucial steps to establish diseases in the infected host. In this study, we identified three genes 
responsible for the ability to colonize the respiratory tract and/or establish systemic infection. 
The genes identified in these mutants were associated with components encoding substrate-
dependent ABC transport systems rather than the direct production of classical virulence 
determinants. Uptake of specific substrates required for metabolic pathways could be critical 
for survival because mycoplasmas possess limited synthetic capabilities for many essential 
molecules and must acquire them from exogenous sources. Thus, substrates that are utilized 
by the genes identified in our studies are most likely to have important biological roles for 
the mycoplasma in dealing with the in vivo environment in the infected host. Further 
characterization of the biological roles of these substrates in M. bovis will open new avenues 
to understand the pathogenicity of M. bovis and other similar mycoplasmas.  
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